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The sex steroidal hormones Estrogen (E2) and Testosterone (T) have been conclusively shown 
to control reproduction and development of secondary sex characteristics in both male and 
female vertebrates. From infancy to adulthood, E2 and T play crucial roles in the proper 
function of the reproductive success of all animals, most notably of course being that of humans.  
Years of research and studies using knock out gene animal models have identified the key 
modulators of E2 and T function.  The gonadotrophs of the anterior pituitary synthesize and 
secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which regulate 
gonadal development, gametogenesis and the synthesis and secretion of the gonadal steroid 
hormones.  LH and FSH secretion is primarily regulated by gonadotropin-releasing hormone 
receptor (GnRHR) and its GnRH ligand secreted from neurons of the rostral hypothalamus. 
Recently, kisspeptin (KISS1)/kisspeptin receptor (KISS1R) signaling in GnRH neurons has 
been shown by our group and others to play an essential role in HPG axis function.  However, 
whether kisspeptin signaling via the Kiss1r could also regulate reproductive function at the 
level of pituitary is not yet established. We hypothesized and show in this thesis that KISS1R 
in the pituitary is integral to the proper function of the pituitary. KISS1 signaling in conjunction 
with the workings of the HPG axis are able to exert powerful effects on the reproductive 
capabilities of vertebrates. New findings however have begun to implicate sex steroid signaling 
in functions such as the control of metabolic parameters like glucose homeostasis, adiposity, 
and energy expenditure. In the clinic, metabolic diseases and infertility as often observed 
together. Defective E2 and T signaling is now being implicated in clinical cases of metabolic 
syndrome, polycystic ovarian syndrome (PCOS), and type 2 diabetes (TD). Changes in 
metabolic function are observed in response to gonadectomy, or normal changes such as 
puberty, menstrual cyclicity and menopause. However, the signals that link reproductive status 
and metabolic function are not well understood.  Because the liver is a major metabolic organ, 
we hypothesized that hepatic E2/ESR1 signaling regulates proper hepatic function, including 





axis and metabolic function.  Finally, we successfully modeled PCOS like metabolic defects of 
hyperandrogenemia in female mice, by implanting pellets of dihydrotestosterone (DHT) in 
these mice. We then correct the glucose and energy metabolic defects by ablating the androgen 
receptor in the central nervous system of these mice. These findings offer new insights as well 
as potential targets into the ability of sex hormones, mediated by Kisspeptin and androgens, to 
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Sex Steroid Hormones: Estrogen (E2) and Testosterone (T)  
The blood borne hormones estrogen (E2) and testosterone (T), classically known as the 
“sex steroid hormones,” have been conclusively studied and shown to have powerful effects on 
the sexual development and function of vertebrate physiology (Couse & Korach, 1999). The 
influences of steroid hormones can be ascertained from the earliest stages of fetal life 
throughout adulthood.  Both the control of adult reproductive organ function as well as the 
development of secondary sex characteristics are the result of E2 and T action. In females, the 
estrous cycle, development of the ovaries, and maternal behaviors are all under the control of 
E2 action (Koos, 2011; Porter, 1974; Simpson et al., 2005). In males, the proper development 
of the gonads, the proper maturation of sperm, as well as mating behaviors have all been 
attributed to the action of T.(Gottlieb, Lombroso, Beitel, & Trifiro, 2005; Quigley et al., 1995)  
The tissue targets of E2 and T are numerous and varied since their receptors are widely 
distributed, thus the actions of both E2 and T must be considered in both males and females.  
Beyond their canonical roles in reproduction, a growing body of evidence suggests that 
E2 and T also influence metabolism and contribute to glucose homeostatic functions.  Clinical 
evidence in women has shown that hypoestrogenemia in postmenopausal women leads to 
increased obesity and cardiovascular risk,(Gruber, Tschugguel, Schneeberger, & Huber, 2002; 
Soderqvist, von Schoultz, Tani, & Skoog, 1993) and hyperandrogenemia results in Polycystic 
Ovarian Syndrome (PCOS)(Goodarzi, Dumesic, Chazenbalk, & Azziz, 2011; McCartney & 
Marshall, 2016). Males can also suffer from defective hormone signaling. Men with estrogen 
insensitivity have been shown to be at a greater risk of osteoporosis, to have decreased glucose 
tolerance, and to have increased levels of circulating insulin (Faustini-Fustini, Rochira, & 
Carani, 1999; Rochira & Carani, 2009).  Although clinical studies suggest that sex steroid 
hormones play crucial roles in metabolic functions, the mechanisms of how sex steroid 
hormones regulate reproductive and metabolic function are not yet fully understood.  One aim 





the role of T in female metabolism under conditions of androgen excess (referred to as 
hyperandrogenemia). 
 Regulation of Estrogen and Testosterone by Hypothalamic Pituitary Gonadal Axis 
(HPG) 
The control of reproduction is the responsibility of the hypothalamic-pituitary-gonadal 
axis (HPG) as diagrammed in Figure 1.1. At the top of this axis are neurons of the hypothalamus 
which secrete gonadotropin-releasing hormone (GnRH) in a pulsatile manner (Clarke & 
Cummins, 1982). The synthesized hormone travels along the neuronal axon and is released into 
the median eminence, which reaches the GnRHR on the pituitary gland to stimulate the 
synthesis and release of two factors—LH and FSH. Both LH and FSH then enter the blood 
circulatory system before binding to their receptors—on the ovaries in females and on the testes 
in males (Baird, Swanston, & Scaramuzzi, 1976; Leipheimer, Bona-Gallo, & Gallo, 1984). E2 
and T are primarily synthesized at the gonadal level. As will be expanded on later, there is 
hormonal feedback in females—and to a lesser extent in males—which controls the timing and 
amount of E2 and T production.  GnRH is released in a pulsatile manner from the hypothalamus 
into the hypophyseal portal system of microcirculation at the base of the brain, after which it 
binds to GnRHR on the surface of gonadotrophs of the pituitary gland (Nippoldt, Reame, Kelch, 
& Marshall, 1989). The binding of GnRH to GnRHR elicits intracellular calcium signaling that 
leads to the secretion of LH and FSH from the pituitary gland (Baird et al., 1976). Both of these 
gonadotropins then reach the gonads by general circulation.  
In males, LH causes the release of T from the Leydig cells of the testes (Rochira & 
Carani, 2009). The HPG axis assists to fine tune the total amount of T in circulation, which is 
accomplished by T negatively feeding back on pituitary LH production and hypothalamic 
GnRH secretion in order to reduce the levels of circulating T. Furthermore, FSH has been 
shown to stimulate secretion of the hormone inhibin from sertoli cells (Makanji et al., 2014). 





 In females, hormonal regulation involves the interplay of both negative and positive 
feedback in order to facilitate the essential rise and fall of E2 levels in reproductive female 
physiology. E2 levels vary through the menstrual cycle, with levels highest near the end of the 
follicular phase just before ovulation (Clarke & Cummins, 1982). Feedback occurs at the 
ovarian theca cells and granulosa cells where progestins and inhibin are respectively produced 
(Watson & Stacy, 2010). Similar to its actions in males, increases in inhibin levels result in 
decreased FSH output from the gonadotroph cells of the pituitary gland. Increased levels of E2 
and progesterone synthesis and secretion have been observed in the early to mid-follicular 
phase of the female menstrual cycle. This increase serves to inhibit LH and FSH secretion from 
the pituitary. 
 As the menstrual cycle progresses from the follicular to the luteal phase, there is a rise 
in LH and FSH levels leading to a decrease in E2 production. The most notable change in LH 
and FSH levels is seen during the preovulatory surge. There is a neuroendocrine switch which 
toggles from a negative to a positive feedback loop, causing E2 levels to rise dramatically and 
allowing for follicular ovulation to occur. The effects of increased positive feedback are further 
amplified by increased sensitivity to GnRH stimulation by the LH secreting pituitary 
gonadotrophs (Homburg, 2005). However, this form of signaling is not always infallible. 
Defective feedback signaling has been noted in the clinical setting as well as in mice models. 
For example it is unsurprising to find that in women with PCOS, increased GnRH release is a 
marker of metabolic syndrome. Such an increase in GnRH release causes alterations in LH and 
FSH levels, leading to irregular menstrual cycles (Blank, McCartney, & Marshall, 2006; 
Shayya & Chang, 2010). The fine tuning of the female menstrual cycle is demonstrative of the 
powerful ability hormonal feedback has to control hormone synthesis. 
Kisspeptin 
Of particular interest in this thesis is the role of the secreted peptide kisspeptin (KISS1) 
in the regulation of the HPG axis. While originally discovered in 2003 by the cancer field, when 





neuroendocrinologists due to its clear and powerful effects on GnRH neurons (Cravo et al., 
2011; Iwata, Kunimura, Matsumoto, & Ozawa, 2017). Kisspeptin-expressing neurons reside in 
the anteroventral periventricular nucleus (AVPV) and the arcuate nucleus (ARC) of the 
hypothalamus, and send neuronal projections to the GnRH neurons (Pasquier et al., 2014). It 
should be noted that only female hypothalami contain an ARC. KISS1, through its G-protein 
coupled receptor KISS1R (formerly GPR54), has been shown to be a key regulator of pubertal 
onset via the homeostatic regulation of the HPG axis and generation of the preovulatory LH 
surge.  
It has recently been shown by our group that disruption of Kiss1R in GnRH neurons in 
mice results in failure to progress through puberty due to hypogonadotropic hypogonadism 
(Novaira, Ng, Wolfe, & Radovick, 2009). This demonstrates that KISS1 is essential to the 
initiation of gonadotropin (LH/FSH) secretion at puberty. KISS1/KISS1R are expressed in a 
wide range of reproductively active tissues in the brain, pituitary, ovary, and testes, however 
they are also expressed in metabolically active tissues within the liver, pancreas, and fatty 
tissues (Ohtaki et al., 2001). In the mouse, hypothalamic (central) Kiss1 expression is acutely 
regulated by E2 signals, which are mediated by the E2 receptor (ESR1) (Wintermantel et al., 
2006). The role and regulation of KISS1 within non- hypothalamic (peripheral) sources is only 
beginning to be understood. In Chapter 2 we provide evidence for a role of the pituitary KISS1R 
in mediating signals to the pituitary and thus affecting its function. Utilizing cre-lox 
recombinant technology we ablated KISS1R in the pituitary gonadotrophs, creating a new 
mouse model termed PKIRKO (Pituitary Kisspeptin Receptor Knockout).  
Work from our group has shown that the liver is a source of circulating KISS1 and that 
hepatic KISS1 serves to regulate glucose stimulated insulin secretion (Song et al., 2014). 
Considering the important role of hypothalamic KISS1 in regulating reproductive function, 
these results raise the possibility of interplay between the metabolic and reproductive functions 





Chapter 3 we propose that E2 directly regulates hepatic KISS1 expression as well as the 
expression of other gluconeogenic genes.  
Steroidogenesis: Estrogen and Testosterone Biosynthesis 
  The majority of E2 and T is derived from the carbon-19 steroid hormone cholesterol 
(Mendoza-Hernandez, Calcagno, Sanchez-Nuncio, & Diaz-Zagoya, 1984).  The synthesis of 
either E2 or T depends not only on the tissue type (for example, testicular versus ovarian tissue), 
but also on the cellular location (for example, mitochondria vs. smooth endoplasmic reticulum) 
of a series of enzymes which ultimately convert cholesterol into active metabolites such as 
mineralocorticoids, glucocorticoids, estrogens (E2), androgens (T), or progestogens (Figure 
1.2). Although each group of the aforementioned metabolites of cholesterol conversion are 
important to vertebrate physiology, of most relevance to this thesis is the biogenesis of 
estrogens and androgens. 
 In females, E2 and T synthesis begins in the mitochondria of theca interna cells of the 
ovary, where a protein called stAR facilitates the transport of cholesterol from the outer 
mitochondrial membrane to the inner mitochondrial membrane (Chang, T. Y., Chang, Ohgami, 
& Yamauchi, 2006; Miller, 2007). Once inside the inner mitochondrial membrane, the synthesis 
of androstenedione from cholesterol by the enzymes 17α-hydroxylase and by 17β-
hydroxysteroid dehydrogenase (17β-HSD) is able to occur (Pollow, Lubbert, & Pollow, 1975). 
The gene Cyp17 is the source of 17α-hydroxylase. The main role of androstenedione is to serve 
as a precursor for the synthesis of both androgens and estrogens. In the female ovary, 
androstenedione travels from the theca cells into granulosa cells. It is inside granulosa cells 
where androstenedione is converted via aromatase to three estrogenic compounds (Mindnich et 
al., 2005). Those compounds are 17β-estradiol, estrone, and estriol. In terms of estrogenic 
potency, 17β-estradiol is the most potent estrogenic compound, and is followed by estrone and 
estriol (Miller & Auchus, 2011). 
  It is important to note that during pregnancy, a fourth type of estrogen called estetrol 





generally considered a weak hormone because its levels are only detectable during pregnancy, 
and because there are low affinities for its receptors, those being Estrogen receptor alpha 
(ESR1) and E2 receptor beta (ER-β) (Warmerdam, Visser, Coelingh Bennink, & Groen, 2008). 
In addition the corpus lutea, a structure that is maintained in the ovary during pregnancy, 
produces an important reproductive hormone called progesterone (Baulieu & Schumacher, 
2000). Progesterone is catalyzed from pregnenolone via 3β-hydroxysteroid dehydrogenase 
action in the corpus luteum (Pang, 2001). Smaller amounts of progesterone are also produced 
by the adrenal glands during mineralocorticoid synthesis. Progesterone has been referred to as 
a “pregnancy hormone” because of its strong actions on female anatomy during pregnancy. 
Those actions include inhibiting lactation in the mammary glands until postpartum as well as 
inhibiting the movement of uterine smooth muscles during delivery (Patel et al., 2015).  
The production of female T results from the conversion of androstenedione to 
testosterone by 17β-HSD from theca cells (Miller & Auchus, 2011). The compartmentalization 
of aromatase and 17β-HSD in vertebrates allow for the endogenous dual production of both E2 
and T. The aromatase gene CYP19 encodes for the aromatase enzyme and is found in numerous 
tissues in the body including those of the brain, breast, adipose, muscle and bone (Bulun et al., 
2003). This peripheral expression of aromatase also allows for E2 production in males, as will 
be expanded on below. The importance of aromatase to steroidogenesis has been well 
highlighted in knockout mouse models and in studies of aromatase inhibition. Such studies 
conclusively show that both aromatase knockout in mice (Fisher, C. R., Graves, Parlow, & 
Simpson, 1998; Jones et al., 2001) and pharmacological inhibition (Ferretti et al., 2006) of 
aromatase lead to underdeveloped external genitalia/uteri (Ryan, 1982) and hypoestrogenism 
(Rochira, Balestrieri, Madeo, Spaggiari, & Carani, 2002), or estrogen deficiency (Smith et al., 
1994). Interestingly, metabolic disturbances such as obesity (Fisher, C. R. et al., 1998), elevated 
lipid levels (Simpson et al., 2005), and impaired glucose metabolism have been noted in these 





associated with infertility are a key area of interest and study for both our lab and many other 
research institutes.  
While E2 is typically considered to be a primarily female hormone, the respective 
conversion of testosterone and androstenedione to estradiol and estrone is also possible in males 
due to the expression of aromatase by peripheral tissues (Miller & Auchus, 2011). In the male 
reproductive tract, aromatase is highly expressed in the Leydig cells, Sertoli cells, and 
spermatocytes. The osteoblast and osteoclast cells of the bone as well as the adipocytes of 
adipose tissue are also sites of E2 production in males (Simpson et al., 2005) .  Male E2 and/or 
ESR1 knockout animal models have yielded interesting but conflicting results. Thus, E2 action 
in males must be considered and further studied.  
As noted in figure 1.2, there are other androgen metabolite precursors which also 
circulate in the bloodstream, such as dehydroepiandrosterone (DHEA) and dihydrotestosterone 
(DHT). DHEA is produced not only in the ovary but also in the zona reticularis of the adrenal 
glands. DHT is primarily produced in peripheral tissues (skin and prostate) via the conversion 
of T to DHT by the enzyme 5α-reductase. We and other labs utilize DHT (Andrisse et al., 2017) 
in animal studies of androgen action because of its inability to be converted to E2 by 
aromatization and higher binding potency to androgen receptors (AR) (Burger, 2002), thus 
allowing for the sole analysis of androgen signaling. As is already well understood, both T and 
DHT play major roles in the development of male sexual characteristics (Luetjens & 
Weinbauer, 2012). Such sexual characteristics include the development of male reproductive 
tissues (such as those of the testes and prostate), increases in muscle and bone mass, and the 
growth of body hair (Mooradian, Morley, & Korenman, 1987). Within the blood circulatory 
system, over 98 percent of E2 and T is bound to either albumin or sex hormone binding globulin 
(SHBG). Free unbound sex steroids make up about 2 percent of all sex hormones found in 
vertebrates (Luetjens & Weinbauer, 2012). The free unbound hormones are able to directly 






Nuclear Receptor Signaling: Estrogen Receptors (ESR1/Erα, ESR2/Erβ and GPER) 
 For E2 to cause changes in target cells, it must first activate estrogen receptors (ER) 
inside of the cell. This is accomplished by binding to ERs known as estrogen receptor alpha 
(ESR1/ERα) and estrogen receptor beta (ESR2/ERβ) (Green et al., 1986).  Of recent is the 
discovery of a non-genomic ER signaling pathway mediated by membrane localized G protein-
coupled estrogen receptor 1 (GPER1, GPR30) (Liu et al., 2009). ESR1 and ESR2 behave like 
most classic steroid receptors by directly navigating the cell lipid membrane in order to enter 
the cytosol (Kumar, Green, Staub, & Chambon, 1986). After dimerization, ER binds E and 
enters the nucleus, directly binding to estrogen response elements (EREs) and regulating the 
transcription of the target gene. EREs have been shown to be evolutionary conserved among 
chordates and contain the consensus sequence of 5’GGTCAnnnTGCACC-3’ (Driscoll et al., 
1998).   Both ESR1 and ESR2 have a zinc finger type motif in the DNA binding domain (DBD) 
in conjunction with an N-terminal transactivation domain (AF1) allowing for further 
stabilization of ERs to their target promoters (Mangelsdorf et al., 1995; Nilsson et al., 2001). A 
c-terminal ligand binding domain (LBD) allows for binding with co-factors and other 
transcription activating proteins (Nilsson et al., 2001).  Ultimately, it is this protein-DNA 
complex in conjunction with chromatin and histone modifications that affect transcription of 
ER regulated genes.  
Known differences between ESR1 and ESR2 include the sharing of only 56% percent 
of the DNA-binding domain (DBD) (Monroe et al., 2005), as well as that ESR1 elicits the 
proliferation of cell lines, while ESR2 inhibits such proliferation (Faulds, Olsen, Helguero, 
Gustafsson, & Haldosen, 2004; Strom et al., 2004). Besides these structural differences, there 
are also vast differences between in tissue distribution between ESR1 and ESR2.  Expression 
of ESR1 can be found in the ovarian theca cells, uterus, breast, bone, Leydig cells, white adipose 
tissue, pituitary gland, adrenal gland, heart, and brain. Expression of ESR2 is predominantly 





liver expresses ESR1 and GPER1, while ESR2 expression is undetectable (Prossnitz & Barton, 
2014). 
In general, the study of E2/ESR1 signaling has been limited to its roles as a 
reproductive influencer, and their roles in metabolism are understudied. Knockout models of 
ERs have been conducted to implicate their roles in both males and females. Lubahn et al, 
produced mice lacking ESR1 and termed them αERKO (Lubahn et al., 1993). They found that 
both sexes of αERKO are infertile due to the lack of ovulation in females and disrupted mating 
behavior in males. Furthermore, they found that both sexes had decreased bone weight and 
density. These were just a few of the physiological consequences of the deletion of ESR1. 
Deletions of ESR2 yielded milder results. Krege et al have shown in their ESR2 knockout mice 
that while females were sub fertile, the males remained fertile and displayed normal mating 
behavior (Krege et al., 1998) The mammary glands in female αERKO mice were described as 
being immature, while those of ESR2 knockouts had normal structure and normal lactation. 
Several studies in both sexes have shown that the liver is an E2 responsive organ 
(Ciocca & Roig, 1995; Fisher, B., Gunduz, Saffer, & Zheng, 1984; Francavilla et al., 1986). In 
males, emerging studies—including our labs finding that hepatic ESR1 is crucial for regulation 
of hepatic gluconeogenesis and lipid metabolism in males—indicate that ESR1 signaling is 
important for homeostasis (Qiu et al., 2017). Knockout studies of E2 in males showed that 
perturbation of ESR1 resulted in obesity (Della Torre et al., 2016; Stubbins, Holcomb, Hong, 
& Nunez, 2012), metabolic dysfunction (Gallagher et al., 2007), and increased risks of chronic 
diseases (Keene et al., 2008). A seminal study was conducted by Hewitt and colleagues in 
which they demonstrated that in mice in which the aromatase gene has been deleted (ArKO), 
the development of hepatic steatosis could be normalized by estrogen treatment in male 
knockout mice but not female knockout mice (Hewitt, Pratis, Jones, & Simpson, 2004). 
Furthermore male mice with liver-specific ESR1 knockout display increased accumulation of 
fat in the liver as well as irregular insulin signaling under high-fat diet (HFD) feeding (Zhu, 





In post-menopausal women, there is a gradually increasing deficiency in estrogen 
levels. Recent data has suggested that these women are more likely to suffer from mitochondrial 
dysfunction, cellular senescence, declining immune responses to injury, an in-balance between 
antioxidant formation, and oxidative stress (Brady 2015).  All these defects during menopause 
dramatically affect the liver. Liver physiology and morphology is altered in post-menopausal 
women. The volume, blood flow, and function of the liver decrease by approximately 1% per 
year after about age 40 to 50 (Iber, Murphy, & Connor, 1994). Furthermore, liver volume 
decreases by 20% to 40% in an elderly person, with this reduction being more significant and 
noticeable in women (Uebi, Umeda, & Imai, 2015). Unfortunately, progression of nonalcoholic 
fatty liver disease and hepatocellular carcinoma have been shown to be more severe in post-
menopausal women (Yang et al., 2014).  
Taken together, these aforementioned studies suggest that estrogen plays a protective 
role in both sexes. Uebi et al concluded that E2 regulates liver protein turnover, supports 
hepatocyte proliferation, and is highly involved in hepatic recovery after injury (Uebi et al., 
2015). Knowing the clear impact of E2 on hepatic success, studies such as ours discussed in 
Chapter 3 provide further insights into the action of E2/ESR1 signaling in the liver. In Chapter 
3 we provide evidence for the E2 regulation of the hepatic hormone Kisspeptin.  
Nuclear Receptor Signaling: Androgen Receptor 
 The actions of T on responsive cells and tissues are mediated by NR3C4 (nuclear 
receptor subfamily 3, group C, member 4), also known as the androgen receptor (AR). AR 
expression can be found all over the body in both males and females. In humans, AR mRNA 
and protein can be detected in the brain, reproductive tissues, bone marrow, lung, muscles, 
liver, pancreas, and the gastrointestinal tract. The mRNA of AR was cloned by Liao et al in 
1988 (Chang, C. S., Kokontis, & Liao, 1988) and the crystal structure was resolved in 2000 by 
a team of researchers in Germany and Portugal (Matias et al., 2000). AR contains the conserved 
N-terminal domain, DNA-binding domain, and androgen-binding domain in order to regulate 





knowledge of AR structure has further solidified its actions as a classic steroid receptor 
hormone. Behaving in a similar manner as ER, AR can bypass the hydrophobic lipid membrane 
bilayer in order to dimerize in either the nucleus (Genomic AR signaling) or the cytosol 
(Nongenomic AR signaling).   
 Classical genomic signaling of AR acts as a steroid-hormone activated transcription 
factor. Once inside the nucleus, AR binds to androgen response elements (ARE) (De Bruyn, 
Bollen, & Claessens, 2011). The ARE is composed of two 5′-AGAACA-3′-like motifs, which 
are separated by three bps. (Claessens et al., 1996) Due to their proximity to promoters of 
androgen responsive genes, ARs are able to recruit and effect transcription machinery to 
ultimately regulate the target gene. As aforementioned, the ligand for AR is T, however its 
metabolite DHT has a greater affinity for AR than T. The EC50 of DHT for activation of the 
AR is 0.13 nm, while conversely the EC50 of T for AR activation is 0.66 nM. (Wilderer, 2010) 
Thus, it is not surprising that bioassays of AR activation reveal that DHT is overall more potent 
than T (Grino, Griffin, & Wilson, 1990). 
 Although not as clearly defined as the genomic actions of AR, there is growing 
evidence that AR can act through non genomic pathways. As reviewed by Lu et al, both 
membrane and cytoplasmic AR signaling can exert powerful effects on cellular activity 
(Freeman, Cinar, & Lu, 2005).At the level of the cell membrane AR has been postulated to bind 
to an unidentified G-protein couple receptor leading to rises in intracellular calcium (Benten et 
al., 1999). When not bound by heat shock protein 90 (hsp90) (Heemers & Tindall, 2007), AR 
in the cytoplasm is able to bind to intracellular molecules such as Proto-oncogene tyrosine-
protein kinase Src—otherwise known as c-Src (Wheeler, Iida, & Dunn, 2009). Auricchio et al 
demonstrated that the c-Src SH2 (Src Homology 2) domain binds to a proline rich stretch of 
AR leading to activation of the tyrosine kinase complex (Migliaccio et al., 2000). The ability 
of AR to behave in non-classical steroid hormone signaling pathways suggests that T/DHT 





 In Chapter 4 we propose that AR in the central nervous system is a mediator of DHT 
effects on glucose and energy metabolism in female mice. We utilized cre-lox technology to 
delete AR expressed specifically in the central nervous system. We termed our knockout mice 
SYNARKO (Synapsin AR knockout). As shown in Figure 1.3, we have developed a DHT 
regiment in order to model hyperandrogenemia in female mice. It is important to note that this 
low dose DHT model allows us to study AR signaling without having to compensate for the 
effects of obesity. We show that DHT effects on glucose intolerance and energy expenditure 
are ameliorated by ablating AR in the central nervous system, thus further implicating the 
importance of sex steroids in instances of metabolic syndrome.  
Summary 
 Both E2 and T are crucial to the proper development and maintenance of the physiology 
of male and female reproduction. The HPG axis along with the secreted hormone Kisspeptin 
have been shown to control and regulate E2 and T’s roles in reproduction. There is, however, 
mounting evidence that E2 and T’s roles are not limited to the control of reproduction.  In the 
clinic, comorbidity between metabolic diseases and infertility is often observed. Infertility 
caused by Type 2 Diabetes or by PCOS is commonly associated with metabolic dysregularities 
such as insulin resistance. However, the signals that link reproductive status and metabolic 
function are not well understood. Work from our lab and others have implicated that both E2 
and T signaling contribute to the metabolic homeostasis of animals. We first defined a novel 
role for peripheral KISS1/KISS1R signaling action in the pituitary and the liver. We 
demonstrated that KISS1 is indeed involved in both reproductive and metabolic functions. 
Finally, we used knockout mice models that use homologous recombination in embryonic stem 
cells in order to analyze the effects of the absence of E2 and T on the on the reproductive and 
metabolic physiology of the animals. We further modeled the pathophysiological conditions of 
hyperandrogenemia in order to elucidate the role of sex steroids in metabolic defects.  It is my 





reproductive disorders associated with metabolic issues such as PCOS, type 2 diabetes and 
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Schematic of the hypothalamic pituitary gonadal axis. Modeled is the Estrogen regulation of 
hypothalamic Kiss1, which plays an important role in mediating estrogen feedback regulation 













Overview of steroidogenesis. Diagramed are the different pathways from which the sex 
steroids are generated from cholesterol and transformed into other steroids. Noted are the 























For the experimental design, 4-mm DHT pellets and 4-mm empty pellets (control) were inserted 
subcutaneously between the ears of the mice. The following tests were conducted over a 3-
month period: Vaginal smears were evaluated for 16 days for determination of estrous cyclicity; 
blood was obtained weekly for the assessment of serum hormone levels, glucose, insulin, and 
pyruvate tolerance tests were performed to assess whole-body glucose homeostasis, pellets 
were replaced and reinserted every month; and at 3 months after the original insertion, tissues 
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The anterior pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 
contributes to the regulation of gonadal development, gametogenesis and the secretion of the gonadal 
steroid hormones.  The gonadotroph is primarily regulated by hypothalamic secretion of gonadotropin-
releasing hormone (GnRH) from neurons of the rostral hypothalamus and is mediated by GnRH 
receptor signaling. Recently, kisspeptin (KISS1)/kisspeptin receptor (KISS1R) signaling in GnRH 
neurons has been shown by our group and others to play an essential role in hypothalamic-pituitary-
gonadal (HPG) axis function.  However, whether kisspeptin signaling via the KISS1R could also 
regulate reproductive function at the level of pituitary is not yet established. Using Cre/Lox technology, 
we knocked out the Kiss1r gene in pituitary gonadotropes (PKiRKO). Our results revealed that 
PKiRKO males have normal external genital development, have normal ages of puberty as assessed by 
preputial separation and also have comparable body and testes weight to control male mice. While there 
were no differences in basal serum LH and FSH levels, we observed a significant attenuation (P＜0.05) 
in GnRH stimulated luteinizing hormone (LH) levels in PKiRKO male mice compared with Control 
male mice. To directly assess cellular response, calcium (Ca2+) assays were performed on primary 
pituitary cells cultured ex vivo, and demonstrated that pituitary cells from Control male mice were 
sensitive to kisspeptin, GnRH and pituitary adenylate cyclase-activating peptide (PACAP). Pituitary 
cells from PKiRKO male mice exhibited reduced or absent calcium responses to the aforementioned 
peptides.   Overall, these findings indicate that the pituitary KISS1R may plan an important modulatory 
role in augmenting pituitary responsiveness.   
Introduction 
Pubertal onset is marked by an increase in the frequency and amplitude of gonadotropin-releasing 
hormone (GnRH) pulses by the hypothalamus, which is followed by increased secretion of the 
gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by the anterior 





and its G-protein coupled receptor (GPCR), the kisspeptin receptor (KISS1R/GPR54) have a critical 
role in regulating the hypothalamic-pituitary-gonadal axis in all mammalian systems (Funes et al., 
2003; Messager et al., 2005; Gottsch et al., 2004; Smith et al., 2007.). Loss of function mutations of 
Kiss1r are associated with lack of puberty onset and hypogonadotropic hypogonadism in humans and 
rodents, whereas gain-of-function mutations produce precocious puberty in humans (Seminara et 
al.,2003;de Roux et al.,2003; Teles et al.,2008; Silveira et al.,2010.). In rodents, Kiss1r is highly 
expressed in hypothalamus and its role in regulating the reproductive hormone axis is firmly established 
(Dror et al., 2013). Conditional knock-out studies have clearly defined a role for Kiss1r expression in 
the GnRH neuron for reproductive development and fertility (Clarkson et al., 2009; Novaira et al., 
2014.).  Besides the hypothalamus, pituitary and gonads, Kiss1r is also detected in placenta, liver, 
pancreas and intestine where its role is less clear. 
GnRH neurons located in the hypothalamus have long been thought to be the final neuroendocrine 
output regulating the HPG axis. This has resulted in few studies exploring the role of Kiss1r in the 
pituitary. However the ability of the pituitary to incorporate diverse cues and signals to affect 
reproductive output is gaining more attention. These cues and signals include gonadal hormones such 
as estradiol (Singh et al., 2009), testosterone (Ramaswamy et al.,2007.), progesterone (Girmus & Wise 
et al.,1992) and inhibin (MacLachlan et al.,1987), metabolic hormones such as insulin (Brothers et 
al.,2010.), and locally produced proteins such as activin (Bilezikjian et al.,2011.) Alternatively, the 
pituitary is accessible to be acted upon by circulating KISS1, thus activating KISS1/KISS1R signaling 
cascades. Both KISS1R and GnRHR are G-protein-coupled receptors (GPCRs) containing the 
prototypical seven transmembrane regions and can activate several GPCR mediated signaling 
pathways. Additionally, a number of other hypothalamic regulatory factors such as corticotropin-
releasing hormone (CRH) (Hauger et al., 1993.), dopamine (Pivonello et al., 2004.), and pituitary 
adenylate cyclase-activating peptide (PACAP) (Harada et al., 2007.) also act via specific GPCRs.  
Witham et al have demonstrated that kisspeptin increases gonadotropin gene expression in mouse 





expression is enhanced in the pituitary of female mice during the estradiol-induced LH surge (Clarkson 
et al., 2008.), suggesting a possible role for kisspeptin as part of the constellation of regulatory inputs 
to the pituitary required for the massive preovulatory release of gonadotropins. Our studies using a 
novel kisspeptin receptor knockout mouse model (PKiRKO mouse) provide evidence that kisspeptin 
signaling augments pituitary gonadotroph responsiveness and may play a role in regulating the male 
HPG axis.  
Although both male and female PKiRKO mice were produced, only the male model was shown to 
have nearly complete knockout of Kiss1r in the pituitary gonadotroph and therefore we present here 
findings primarily from the male PKiRKO mouse. Knowledge of the precise role of kisspeptin and the 
kisspeptin receptor at the level of the gonadotroph will help define the complex regulation of 
mammalian reproduction at the level of the pituitary. 
Materials and Methods 
Generation of Gonadotrope-specific Kiss1R knockout mice (PKiRKO) 
To generate pituitary Kiss1 receptor (Kiss1R) knockout (PKiRKO) mice, we crossed 
heterozygous floxed Kiss1r (fl/wt) female mice (Singh et al., 2009) with αGSU transgenic (αCre+/-) 
male mice (Pivonello et al., 2004; Quennell et al., 2011.).  F1: female mice (Kiss1r fl/wt; αCre+) and 
male mice (Kiss1r fl/fl; αCre-) were crossed to produce PKiRKO mice (Kiss1r fl/fl; αCre+). Litter 
mates (Kiss1r fl/wt; αCre- and Kiss1r fl/fl; αCre-) were used as Controls. Heterozygous knock out mice 
(Kiss1r fl/wt; αCre+) mice were not included in these studies. Genotyping primers were designed to 
detect the presence of the floxed allele, WT allele, or knockout allele of Kiss1r: P1 sense (located in 
exon 1) and P3 antisense (located in exon 3).  Using genomic DNA obtained from extra-pituitary organs 
(eg. tail), primers P1 and P3 amplify a 2096-bp amplicon (floxed Kiss1r allele) and 1882-bp band (WT 
allele) and a 1120-bp amplicon (KO allele, if the sequence between the LoxP sites is excised). Primer 






Adult male and female mice (>2 months old) were used in this study. All animal studies were 
carried out in accordance with National Institutes of Health guidelines on animal care regulations and 
were approved by the Animal Care and Use Committee of the Johns Hopkins University. Mice were 
maintained under constant conditions of light and temperature (14: 10 h light⁄dark cycle; 22 C), and 
were fed a normal chow and water ad libitum. 
Quantitative Real-Time PCR (qPCR)  
RNA was extracted from the pituitary, liver, ovaries, uterus, testes, epididymis, adipose tissue 
and from two hypothalamic fragments encompassing the arcuate and the anteroventral periventricular 
nucleus (AVPV) as described previously. TRIzol reagent (Ambion Life Technologies, Carlsbad CA, 
USA) was used according to the protocol provided by the supplier. 1µg of RNA was reverse transcribed 
to cDNA using an iScript cDNA kit (Bio-Rad Laboratories). Real-time qPCR was performed to 
determine the presence and relative expression levels of Kiss1r mRNA in the various tissues. Real-time 
qPCR was performed in duplicate using SYBR Green Master Mix (Bio-Rad Laboratories) and the CFX 
Connect qPCR machine (Bio-Rad Laboratories). Primer sequences for the selected genes are in Table 
S1. For each primer set, PCR efficiency was determined by measuring a 10-fold serial dilutions of 
cDNA and reactions with between 95% and 105% PCR efficiency were included in subsequent 
analyses. Relative differences in cDNA concentration between Control and PKiRKO mice were then 
calculated using the comparative threshold cycle (Ct) method. In order to compare the difference of 
Kiss1r expression in the same tissue between Control and PKiRKO, a △Ct was calculated to normalize 
for internal control using the equation: Ct (Kiss1R) – Ct (18S). △△Ct was calculated: △Ct (PKiRKO) -
△Ct (WT). Relative Kiss1R mRNA levels were then calculated using the equation fold difference = 2-
△△Ct. 
Pubertal onset and assessment 
Preputial separation (PPS) in males was assessed daily beginning after postnatal day 21. This 
consisted of determining whether the prepuce could be manually retracted with gentle pressure. PPS is 





in rodents is dependent on weight (Marty et al., 2001); hence, the weights of PKiRKO and control 
littermates were assessed once a week in prepuberty (day 21) through adulthood (day 49).  
Hormone assays 
Blood samples were collected from submandibular vein (Naik et al., 2006) between 9:00 and 
10:00 AM and basal levels of serum LH and FSH were measured. The basal and stimulated 
(gonadotropin-releasing hormone (GnRH) stimulation test) blood were collected on different days. For 
the GnRH stimulation test, GnRH (catalog no. L4513–1MG; Sigma-Aldrich) was diluted with PBS to 
a stock solution of 583.7 ng/µL and aliquoted to individual tubes for storage at -20°C. Just before 
injection, stock was diluted with PBS to a final working concentration (0.02 ng/µL). GnRH was injected 
subcutaneously at the nape of the neck at a dose of 200 ng/kg body weight per mouse. Blood was 
collected 15 minutes after injection, spun at 6000g, and supernatant was stored at -20C until use. LH 
and FSH were measured using a Milliplex MAP immunoassay (Mouse Pituitary panel; Millipore, St 
Charles, Missouri) on a Luminex 200IS platform (Luminex Corporation).  The assay detection limit for 
LH was .012 ng/mL and for FSH was .061ng/mL. The intra-assay coefficients of variation (CV) for 
LH and FSH were between 5 % and 9%. Serum E2 levels were measured with a mouse/rat E2 kit from 
Calbiotech (Spring Valley, CA). The sensitivity for E2 was 3 pg/mL. Testosterone levels were measured 
by radioimmunoassay by the University of Virginia Ligand Assay Core (Charlottesville, Virginia).  
Fertility assessment 
To determine whether male PKiRKO mice were fertile relative to controls, 3 Control and 4 
PKiRKO male mice were housed with proven fertile WT female mice for 14 consecutive days (1 male 
and 1 female per cage, total 7 cages) and then were separated. If a pregnancy ensued, one week after 
female gave birth, a new male was inserted. Males were rotated among the 7 cages. The duration of the 
fertility study was 4 months and 4 rotations for each male mouse. 






Wet testicular weights were determined in freshly dissected mice. Testes were fixed in Bouin’s 
solution (SIGMA), and stored at 4°C. Tissues were sectioned to 5µm thickness in their entirety by the 
Johns Hopkins Medical Laboratories Histology Group (Baltimore, Maryland).  
Pituitary 
Pituitary was fixed in 4% paraformaldehyde (Affymetrix, Inc) for 2 hours on ice and immersed in 
30% sucrose overnight. Pituitary was then embedded in OCT at -20°C and sectioned to 6 µm. For single 
labeling for KISS1R, sections of pituitary were incubated with rabbit anti-KiSS1R (Abcam) at 1:1000 
dilution for 30 hours and washed with PBS overnight at 4°C. Secondary antibody (goat anti-rabbit IgG 
Alexa Fluor 594) was added at 1:400 dilution for 2 hours at room temperature.  
For double labeling of KISS1R and LHβ sections were incubated in KISS1R- 1:3000 rabbit anti-
KISS1R (Abcam); 1:2000 biotinylated goat anti-rabbit secondary antibody (vector) and avidin-biotin 
complex (Elite ABC kit, Vector Laboratories) and visualized with nickle/DAB chromagen. 
Subsequently, sections were incubated with LHβ- 1:5000 LHβ (NIDDK-AFP571292393); 1:2000 
Rabbit-Anti Rat secondary antibody conjugated with Alexaflur 568 (Life technologies). Sections were 
imaged with an AxioCamAR camera and exported to AxioVision software.   
Pituitary cell dispersion and culture 
Mice (n=4 per group) were sacrificed by decapitation and pituitaries were immediately excised and 
placed in a 50ml conical tube containing fresh HBSS (Gibco). After brief centrifugation at 600 g for 5 
minutes, the whole pituitaries were transferred to a conical tube containing fresh 10% fetal bovine 
serum containing DMEM.  Before cell dispersion, pituitaries were washed several times with fresh 
DMEM. The whole pituitary was enzymatically and mechanically dispersed using 2mL of both 
collagenase (HBSS with 30mg/ml BSA) and pancreatin (Ca 2+/Mg2+ free HBSS with 4.5 mg/ml 
pancreatin) solutions. The pituitary was then further dispersed with a small magnetic stir bar for 90 
minutes at 37°C and washed in Ca 2+/Mg2+ free HBSS before being transferred into a 15 ml centrifuge 
tube containing fresh 10% FBS DMEM. Cell viability, was always higher than 90% as estimated by 





Tewksbury, MA) was used to coat the surface of the cell culture plates for 2 hours. For LH and FSH in 
vitro secretion verification, pituitary cells were plated at a density of 1x106 cells per well of a six-well 
dish. For the calcium flux assay, cells were plated at a density of ~15,000 cells per well in 384 well 
plate. After allowing the cells to attach for 24 hours in an incubator (37°C and 5% CO2), the cell culture 
media was then changed to media containing KP-10 (EMD Biosciences, Inc., San Diego, CA, USA) 
and different doses of GnRH and/or PACAP -38 (Pituitary Adenylate Cyclase Activating Peptide-38, 
BACHEM- Bubendorf, Switzerland). To validate the health and function of the cells, a GnRH time 
course study was performed on primary pituitary cells harvested from Control male mice. Groups of 
cells were treated with 30nM GnRH, for a duration of 30, 60 and 360 (6 hours) minutes. A significant 
increase in media LH levels was observed in mice pituitary cells when treated 30nM GnRH confirming 
the viability of the cells (Figure 2.18).  
Calcium Flux Assay  
Male primary pituitary cells were plated in 10% FBS DMEM at a density of ~ 15,000 cells 
(100ul/well) overnight in a Matrigel coated 384 well plate. Cells were loaded with the dye fluo-4 
(Ex/Em-480/540) by adding 1X dye-loading solution (BD Calcium Assay kit (BD Biosciences, 
Rockville, MD) and incubating for 1 hour at 37°C. GnRH, KP10 and/or PACAP-38 were added by an 
FDSS (Hamamatsu) machine and the data was recorded simultaneously. The kinetics of intracellular 
calcium flux were calculated using the fluo-4 channels from the FDSS machine. Fluo-4 is 
nonfluorescent when not bound to Ca2+.  A kinetic curve of calcium response to different concentrations 
of agonists was produced.  
Data Analysis and Statistics 
All data are reported as means ± SEM, with ‘n’ representing the number of mice or samples used in 
each of the experimental groups. Data were analyzed by unpaired t tests or a one-way ANOVA with a 
Bonferroni post-test used for 3 or more groups using Prism software (GraphPad Software, Inc, La Jolla, 





fluorescent intensity upon agonist addition was then plotted with Prism software. For all calcium assay 
kinetic curves, maximal 480/540 ratios known as peak intensity were graphed as box plots.  
Results 
Generation of pituitary specific Kiss1r knockout mice  
PKiRKO (Kiss1Rfl/fl;αCre+) mice were generated by Cre recombinase mediated excision of 
exon 2 of the Kiss1r, resulting in loss of function of the Kiss1r gene in pituitary, as shown in the 
schematic diagram of Figure 2.1A. Representative PCR genotyping is displayed in Figure 2.1 B (for 
Kiss1r alleles) and C (for αCre transgene).  
Pituitary and tissue Kiss1r mRNA expression in PKiRKO mice  
Disruption of Kiss1r expression was assessed by real-time quantitative PCR (RT-qPCR) and 
immunostaining. RT-qPCR demonstrated a reduction in Kiss1r mRNA by 88% (Figure 2.2 A) and 64% 
(Figure 2.2 B) in the pituitary of male and female PKiRKO mice (n=8), respectively, compared with 
Control mice (n=8). In contrast, no change in Kiss1r mRNA was observed in other tissues including 
the hypothalamus, adipose tissue, liver, or gonads (P> 0.05, n =4) (Figure 2.2 A and B).  
Immunohistochemistry revealed KISS1R (black signal) presence in gonadotrope cells of control 
pituitary (Figure 2.2 B, E). Reduced levels of KISS1R protein in PKiRKO mice paralleled the mRNA 
levels as shown in (Figure 2.2 C, F). As shown in the immunostaining, a more robust knockout of 
Kiss1r was observed in the male mice than in the female mice. Due to the incomplete knockout of 
Kiss1r in females, we continued our study focused on the male Control and PKiRKO mice.  Female 
analysis of puberty, fertility, gonadotrope levels, ovarian morphology were carried out in parallel 
(Figure 2.11-. Double labeling of LH receptor (LHR) and KISS1R revealed that KISS1R protein levels 
were nearly absent in the pituitary gonadotrophs of PKiRKO males (Figure 2.17).  
PKiRKO mice showed no external morphologic abnormalities  
Reproductive development and function of the male PKiRKO mice was analyzed. External 





(Figure 2.8 A and B). PKiRKO males did not exhibit microphallus or decreased anogenital distance 
compared to Controls. (Figure 2.8). 
Pubertal onset and body/gonad weights are normal in PKiRKO mice 
In males, PPS (preputial separation) is an androgen dependent process that serves as an external 
sign of male puberty onset(Marty et al., 2001).  In males, no significant difference was observed in age 
of PPS between the Control and PKiRKO groups (Figure 2.4A). Because body weight has been 
demonstrated to be highly associated with age of puberty(Castellano et al., 2006), we measured the 
weight of the mice throughout the puberty assessment (Figure 2.3A) and found no difference in body 
weight (Figure 2.3A) and testes weight (Figure 2.3B) between Control and PKiRKO mice. Furthermore 
the numbers of sperm in the seminiferous tubules was not statistically different between Control and 
PKiRKO male mice (Figure 2.11 A). 
  No impaired fertility in PKiRKO mice 
Fertility was further examined in Control and PKiRKO mice using a rotating mating protocol. 
PKiRKO male mice demonstrated a normal ability to produce offspring, as shown in Figure 2.4 B-E. 
Female control mice had the same number of litters with PKiRKO and Control sires (Figure 2.4 C) and 
a similar number of pups per litter (Figure 2.4 E). Female control mice bore their first litter with a 
similar latency after introduction to PKiRKO males or Control males (Figure 2.4 D).  
PKiRKO mice have normal basal serum LH and FSH levels 
Morning serum samples were obtained from non-breeding, post pubertal mice and serum LH and 
FSH hormone levels were determined. Basal serum LH and FSH values in PKiRKO mice were not 
significantly different in PKiRKO males relative to Control mice (Figure 2.5A and B). Although not 
significantly different, there was a trend for lower basal LH and FSH levels in male PKiRKO male 
mice than Control male mice. 
PKiRKO male mice exhibit decreased GnRH responsiveness by the pituitary gonadotrophs 
To further assess pituitary function, GnRH-stimulation tests were performed, and LH levels 





significantly increased after GnRH stimulation compared with the baseline levels of Control mice 
(Figure 2.5A). While basal gonadotropin levels were not different, importantly, there was a significant 
attenuation in the GnRH-stimulated LH serum in male PKiRKO mice when compared to their control 
littermates. There were no significant changes in FSH levels in both Control and PKiRKO males before 
and after GnRH stimulation. (Figure 2.5 B). To understand the mechanism contributing to altered 
pituitary sensitivity, we measured Gnrhr and Esr1 (Estrogen receptor alpha) in pituitary of control and 
PKiRKO mice. Both Gnrhr (Figure 6A) and Esr1 (Figure 2.6 B) mRNA were decreased in PKiRKO 
mice compared with Control mice. 
PKIRKO male primary pituitary cells show differential calcium response ex vitro 
To directly study the effects of disrupted KISS1R signaling on the pituitary gonadotroph, we 
used an ex vivo primary culture system to assess calcium flux dynamics of male Control and PKiRKO 
mice pituitary cells. Over a period of 15 minutes (900 secs) we measured relative Ca2+ levels, including 
maximum Ca2+ amplitude, as assessed by 480/450 ratios of fluo-4 (Kinetic data; Figures 2.7 A-F, Peak 
amplitude; Figures 2.7 G-L). Following a one minute recording of baseline calcium both Control and 
PKiRKO primary pituitary cells were treated with or without KP10 (10nM). When treated with 
kisspeptin (10 nM), calcium levels increased significantly in Control cells (Figure 2.7 C, I), while no 
increase in intracellular calcium was observed following KP-10 treatment in the PKiRKO cells (Figure 
2.7 D, J).  
GnRH, acting through the GnRHR, a GPCR, regulates pituitary expression and secretion of the 
gonadotropins.  Cells were treated with varying doses of GnRH -10, 30 &100 nM as well as a 
combination treatment of 1nM KP10 & 30nM GnRH. As shown in Figure 2.7 A and further quantified 
in Figure 2.7 G, all doses of GnRH caused increased intracellular calcium in Control male cells but not 
in pituitary cells from PKiRKO mice. Co-treatment of 30nM GnRH with 1nM KP10 augmented the 
response relative to 30nM GnRH alone, but only in Control cells.  
PACAP is a peptide that has been shown to directly regulate pituitary gonadotroph function 





100 nM for 900 seconds. Figure 2.7 E and F shows traces of Control and PKiRKO pituitary cells 
respectively. PACAP-38 treatment elicited intracellular calcium increases in Control (Figure 2.7 E) but 
not in PKiRKO male primary pituitary cell cultures (Figure 2.7 F). This difference is quantified in 
Figures 2.7 K and L where there was no significant difference in maximum amplitude of the Ca2+ signal 
between the PACAP treated and untreated wells.  
Discussion 
While kisspeptin was originally discovered by cancer researchers, its most well-established role is 
as a potent activator of the GnRH neuron, and thus as a critical regulator of hypothalamic control of 
reproduction. The role of the KISS1/KISS1R signaling system has widened as investigators have 
identified extra-hypothalamic roles in tissues such as the liver, uterus, testes and ovary (Gutierrez-
Pascual et al., 2007.). In addition, expression of KISS1R in the pituitary gonadotroph (Shacham et al., 
2001) points to the pituitary as a possible target for kisspeptin action. The functional significance of 
pituitary KISS1R is not well defined. To directly evaluate the role of pituitary kisspeptin signaling, we 
developed the PKiRKO mouse model lacking KISS1R in the pituitary gonadotroph. We demonstrate 
that KISS1 signaling at the level of the pituitary may serve a role in modulating GnRH stimulated 
gonadotropin secretion.  
In humans and most mammals hypothalamic GnRH secretion drives the synthesis and secretion 
of the gonadotropic hormones LH and FSH from the secretory cells of the anterior pituitary. GnRH 
binding to the GnRHR at the surface of the gonadotropes activates intracellular signaling pathways 
triggering membrane depolarization and a rapid change in intracellular Ca2+ concentration, eliciting 
secretion of LH and FSH (Shacham et al., 2001). The pituitary, by virtue of its location outside of the 
blood brain barrier, is poised to serve as an integrative sensor for peripheral metabolic status, peripheral 
reproductive status and central signals regulating reproduction. 
While GnRH plays a dominant role in regulating gonadotroph secretion, gonadal hormones and 





Kisspeptin’s growing recognition as having extra- hypothalamic actions, led us to explore whether 
kisspeptin impacts pituitary and gonadotroph function directly. Ian Clarke’s group detected KISS1 in 
the hypophyseal portal circulation of ewes, presumably of hypothalamic origin, and further noted a role 
for KISS1 in stimulating pituitary LH secretion (Smith et al., 2008). However, they noted that the 
concentration in the portal circulation was too low to exert effects at the pituitary. Pituitary KISS1R 
could be a target of either centrally or peripherally derived KISS1.  The source of kisspeptin could be 
hypothalamic or from peripheral tissues such as liver (Song et al., 2014) or gonad (Salehi et al., 2015) 
where kisspeptin could be secreted into the circulation and access anterior pituitary cells.   
Investigators have observed KISS1 induction of LH secretion in cultured primary rat and primate 
pituitary cells(Navarro et al., 2005; Luque et al., 2011) and up-regulation of gonadotropin gene β-
subunits, LHβ and FSHβ gene expression in LβT cells(Witham et al., 2013.), although others have seen 
no direct effect of KISS1 on LH or FSH secretion(Matsui et al., 2004; Thompson et al., 2004.). A 
number of studies have suggested that KISS1 may act directly on pituitary gonadotropes to stimulate 
LH release (Gutierrez-Pascual et al., 2007; Luque et al., 2011; Castellano et al., 2006.) or to increase 
gonadotropin or Gnrhr gene expression (Naor et al., 1980). We found that KISS1R is expressed on 
mouse pituitary gonadotrophs (Figure 2.2 and 2.17) which supports studies in rat (Richard et al., 2008) 
and sheep (Backholer et al., 2009) demonstrating co-expression of LH and KISS1R in the pituitary.   
Global Kiss1r knockout mice have demonstrated KISS1R is vital for normal pubertal onset and 
estrous cyclicity (Messager et al., 2005; d'Anglemont et al., 2009; Lapatto et al., 2007). This phenotype 
was phenocopied in GnRH neuron-specific Kiss1RKO mice (Novaira et al., 2014) confirming an 
essential role for kisspeptin signaling at the level of the GnRH neuron. These studies however do not 
preclude a role for kisspeptin signaling at other levels of the axis including at the level of the pituitary. 
We did not identify a phenotype in female PKiRKO mice, but due to an inadequate knock-out of the 
gene in the female pituitary (Figure 2.2 D), we are not equipped to conclude the receptor plays no role 





normal genital anatomy (Figure 2.8), as well as normal fertility (Figure 2.4). It is possible that a 
complete KO of the receptor in the male would result in changes in neuroendocrine regulation of 
puberty and/or fertility. 
While these physiological parameters were normal, direct assessment of pituitary function 
demonstrates there is a modulatory role for the KISS1/KISS1R signaling system in the pituitary 
gonadotroph. To directly probe pituitary function, a GnRH stimulation test was administered. We 
observed that exogenous GnRH administered to PKiRKO mice was able to elicit increases in basal 
serum LH levels, however, the magnitude of stimulated secretion was significantly attenuated 
compared to Controls (Figure 2.5A). This was not associated with differences in basal gonadotropin 
levels or peripheral serum testosterone between PKiRKO and Control male mice (Figure 2.13) 
indicating the hypothalamic homeostatic set point was not impacted, despite the modulated function of 
the pituitary.  
Our data suggest the decrease in stimulated LH secretion in male PKiRKO mice pituitaries is due 
to the reduced expression of Gnrhr mRNA levels - significantly reduced by up to 40% as determined 
by qPCR (Figure 2.6 A). This finding provides evidence of possible kisspeptin and GnRH signaling 
crosstalk. This crosstalk is not surprising as both KISS1R and GnRHR are typical GPCRs having 
relatively similar intracellular mechanism of action.  KISS1R and GnRHR are stimulated upon 
activation of the homologous heterotrimeric G proteins by a ligand such as an ion, peptide or lipid 
(Kobilka, 2007). This then leads to further activation of downstream signaling pathways (e.g. MAPK, 
PLC, PKC) resulting in cellular responses. Control of Gnrhr expression in the gonadotropes is markedly 
regulated by GnRH itself (Nathwani et al.,2000) with pulsatile stimulation of the GnRHR leading to 
increased concentrations of the receptor, while continuous exposure to GnRH downregulating Gnrhr 
mRNA and gonadotropin secretion(Belchetz et al., 1978). The Clay group demonstrated convincingly 
that GnRH regulation of the Gnrhr gene is dependent on ERK activation of promoter elements in the 





pathway providing a mechanism for crosstalk between KISS1R and GnRHR. Further studies will need 
to be performed to assess the mechanism for KISS1R regulation of Gnrhr expression.  
Gonadal steroid feedback regulation of the pituitary gonadotroph is mediated in large part ERalpha. 
In both males and females pituitary gonadotroph ESR1 is another important determinant of the function 
of the reproductive endocrine gland (Gieske et al., 2008). An interesting study done in male mice by 
Lindzey et al (Lindzey et al., 1998), showed that Esr1 knockout mice had FSH levels that were 20% 
higher than those of WT males. Furthermore LHbeta mRNA and serum LH levels in non-castrated male 
ESR1KO mice were significantly higher than those of their WT male counterparts.  These findings 
conclude that ESR1 is important for normal physiology of male gonadotrophs. As a nuclear hormone 
receptor, ESR1 affects expression of many downstream target genes including the gonadotropin 
subunits LHβ, FSH β and common alpha-glycoprotein (CGA) (Ferris & Shupnik, 2006). We measured 
Esr1 mRNA levels using QPCR and showed there was significantly decreased expression in male 
PKiRKO mice versus Control (Figure 2.6 B).  We propose that reduced KISS1R signaling in the 
pituitary causes a reduction in Gnrhr expression, and coupled with reduced ESR1 action, leads to a 
reduction in LH secretion after GnRH stimulation in PKiRKO males.  A link between pituitary ESR1 
and GnRHR was shown in a study of female mice which found that Esr1 potentiated LH hormone 
release on subsequent GnRH stimulations (Kim et al.,2011) by increasing expression of GnRHR in 
gonadotrophs (Strauss et al., 2018). This mechanism could be similar to our findings of decreased 
GnRH induced LH secretion in the PKiRKO model.  
Calcium is an essential component of the secretory response in pituitary gonadotrophs. Changes in 
intracellular calcium are measured to ascertain overall cell function/activity. Using primary cultured 
pituitary cells, we measured intracellular calcium response to the hypophysiotropic hormones GnRH, 
KP-10, and PACAP-38. Liu et al (Liu et al., 2008) performed one of the few studies to directly assess 





caused an approximately 10% increase in intracellular calcium levels in GnRH neurons mediated by 
activation of phospholipase C.  
Treating primary pituitaries with exogenous kisspeptin (10nM of KP-10) stimulated calcium 
increases in Control cells (Figure 2.7 A, G). However, in PKiRKO cells 10nM KP-10 was unable to 
stimulate an increase in calcium levels (Figure 2.7 B, H) confirming the effects of KP-10 were being 
mediated via the KISS1R. Primary pituitary cells from Control mice were responsive to GnRH and 
exhibited increased intracellular calcium levels in response to increasing doses of GnRH (Figure 2.7 
C,I). In contrast, PKiRKO primary pituitary cells failed to respond to 10, 30 or even 100 nM of GnRH 
(Figure 2.7 D) as quantified by maximal Ca2+ signal in Figure 2.7J. In situ, the pituitary gland is bathed 
in microvasculature by the hypophyseal portal system. This system of blood vessels links not only the 
hypothalamus with the anterior pituitary, but also delivers peripherally derived hormones and 
peptides(Lubahn et al., 1993). It is likely that both kisspeptin and GnRH are concurrently activating 
their receptors on the pituitary. Thus, co-treatment of pituitary cells with both KP-10 and GnRH was 
also tested. Both PKiRKO and Control primary pituitary cells were treated with 30nm GnRH and 1nM 
KP-10. As shown in Figure 2.7 C & I, co-treatment was able to potentiate intracellular calcium increase 
in Control pituitaries. This potentiation of intracellular calcium release after co-treatment was absent in 
PKiRKO mice (Figure 2.7 D, J).  
PACAP-38, before being placed in the VIP family of peptides, was shown to be a strong stimulator 
of pituitary adenylate cyclase leading to increased accumulation of cAMP and in turn downstream 
cellular responses(Miyata et al., 1989). Although still poorly understood, the link between 
KISS1/KISS1R and PACAP signaling has recently gained more attention. Anatomically, neurons 
expressing PACAP in the ventral premamillary nucleus of female mice converged with kisspeptin 
neurons of the arcuate and AVPV nuclei. Cre-Lox deletion of PACAP from the ventral premamillary 
resulted in delayed puberty onset and impaired reproductive function in female, but not male mice(Ross 





and colleagues using mouse LbetaT cells showed that KP-10 treatment led to increases in PACAP 
receptor expression.(Mijiddorj et al., 2017) Both KISS1R and PACAP receptor (PAC1, VPAC1, or 
VPAC2) are GPCR’S(Schytz et al., 2010)] which respond to ligands by activation of adenylyl cyclase 
(AC) in order to increase intracellular cAMP levels. It is known that AC is regulated by G proteins (Gs 
stimulating activity and Gi inhibiting it), thus kisspeptin and PACAP crosstalk could be mediated 
through the AC pathway, but we did not measure AC levels in this study.  
Our findings show that pituitary cells from Control mice exhibited increased intracellular calcium 
in response to PACAP-38 (Figure 2.7 E, K). In contrast, the response of PKiRKO primary cells was 
attenuated at all three different doses of PACAP-38, with no significant increase in Ca2+ in PKiRKO 
cells in response to PACAP-38 treatment (Figure 2.7 F, L). This is similar to the findings for GnRH, - 
a dramatic reduction in response- suggesting common intracellular signaling pathways may be 
impacted due to lack of KISS1R. Therefore, KISS1R may be integral to the ability of the pituitary to 
fully respond to both GnRH and PACAP signaling. These calcium assay findings suggest 
KISS1/KISS1R signaling in the pituitary helps to set a tone for the activity of the gland, with the 
absence of KISS1R resulting in reduced sensitivity and responsivity of the pituitary to KP10, 
GnRH/PACAP. It is possible that multiple phosphorylation cascades, cAMP levels and secondary 
messengers (Hauser et al., 2017) controlled by GPCR’s are affected in PKiRKO male mice.  Whether 
responsiveness to other pituitary-GPCR mediated signals, such as some common small-molecule 
neurotransmitters including monoamines such as serotonin, dopamine, norepinephrine (Seasholtz et al., 
2009), are impacted remains to be found. This finding demonstrates the importance of KISS1R to the 
overall functionality of the pituitary. 
In summary, the results of this study illustrate that disruption of kisspeptin signaling in gonadotrophs 
could play an important modulatory role in regulating pituitary function. Although we did not document 
any reproductive or metabolic defects in the PKiRKO male mice, further investigation into the pituitary 





in male mice. This reduction in pituitary function was exhibited as male PKiRKO mice had a reduced 
responsiveness to GnRH stimulation possibly due to reduced transcriptional regulation of the pituitary 
genes Esr1 and Gnrhr. Direct study of the male PKiRKO pituitary ex vivo additionally revealed that 
the effects of hypophysiotropic hormones on pituitary function were impacted by loss of Kiss1r.  KP-
10 (no effect), GnRH and PACAP-38 (reduced responsiveness) all had differential effects on the 
pituitary cells from PKiRKO mice when compared to those from Control male mice. The lack of an 
observed phenotype in the female PKiRKO mice is not considered conclusive. We may have observed 
a phenotype in females if a more complete KO could have been achieved, and similarly, the phenotype 
in males might have been more pronounced if a more complete KO was obtained. Our studies provide 
a rationale for developing conditional KO models using mouse lines with higher levels of CRE 
expression in the pituitary gonadotroph, such as the Fshb-iCre (Wang et al., 2016) or GnRHR-CRE 
mice(Wen et al., 2008).  Overall this study reveals a potentially important modulatory effect of 
KISS1/KISS1R signaling in the pituitary in male mice that could identify a locus of action for 
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Table 2.1. Primer sequences used for genotyping and for qRT-PCR. 
 
Gene name  Forward primer  Reverse primer 
floxed allele, WT 
allele, or knockout 
allele of Kiss1r   
P1 sense (located in exon 1) 
CTGGTCGGAAACTCATTGGT 
P3 antisense (located in exon 1) 
AGAGTGGCACATGTGGCTTG 
αCre+ transgene GCCACCACCGCCCTGCTTAAGTAA CATCTTCAGGTTCTGCGGGAAAC 
QPCR Primers Forward primer  Reverse primer 
Kiss1r CTGCCACAGACGTCACTTTC ACATACCAGCGGTCCACACT 
GnRHR CAGCTTTCATGATGGTGGTG TAGCGAATGCGACTGTCATC 
ERα CGCCTAGCTCAGCTCCTTCT GATGCTCCATGCCTTTGTTAC 














Figure 2.1 Development of the PKiRKO mouse.  
 (A) Schematic diagrams of constructs used to generate PKiRKO mice. Mice bearing LoxP sites 
flanking exon 2 of the Kiss1r were crossed with transgenic mice expressing Cre recombinase 
specifically in Gonadotrophs (αGSU). (B) Genotyping by PCR analysis of the genomic DNA produced 
a 2096 bp amplicon in mice with a floxed allele and an 1882 bp amplicon in WT mice, also shown are 
both bands present in the heterozygous floxed-Kiss1r. (C) Lane 1-αCre+ transgene negative. Lane 2 & 






Figure 2.2 Pituitary specific disruption of Kisspeptin Receptor.  
 
Kiss1r is reduced in the pituitary of PKiRKO mice. Quantitative RT-PCR analysis of Kiss1r mRNA 
extracted from male (A) and female (D) mouse tissues. Kiss1r was significantly reduced (87.6% for 
male, 63.7% for female) in the pituitary of PKiRKO (KO) mice compared with that in wide type (WT) 
mice, but no difference in Kiss1r expression was observed in other tissues. Data are means±SEM 
relative to the control group as determined by a two tailed Students T-test. (n=8 for pituitary, 
n=4 for other tissues). WT, wild-type; AVPV, anteroventral periventricular nucleus; ND, not detected; 
**P≤0.01;***P≤0.001. Immunostaining of Kiss1r, showing Kiss1r localized to the cytomembrane in 
the WT mice pituitary (B & E). Red fluorescence (Kiss1r) is expressed in the cytomembrane, and blue 







Figure 2.3. No Differences in Body or Gonad Weight  
 
(A) Body weight change over time was not different between PKiRKO (n=15) and control male (n=15). 
(B) The weight of testes were not significantly different between PKiRKO and control male mice (n=6).  
Values are mean ± SEM relative to the control group as determined by a two tailed Students T-







Figure 2.4.  Male PKiRKO Mice Have Normal Fertility.  
 
(A) No significant difference was observed in age of preputial separation (PPS) in males. (28.1 ± 2.2 
[control] vs 27.8 ±2.3 [PKiRKO]) control (n=15) PKiRKO (n=15). (B) Male mice were mated with 
WT female mice for 4 rounds (total 120 days). Each line represents an individual male mouse. The 
black dot represents the day that each litter was born after introduction to female. Number on the top 
of the line represents how many pups in each litter. Top panel is male control mice. Bottom panel is 
PKiRKO male mice. (C) Total numbers of litters per male was not significantly different between 
control and PKiRKO mice during the 120 days. (D) After introduction with WT female, the day of first 
litter was recorded in both groups. (E) Number of pups per litter was also not significantly different 
between control and PKiRKO mice. Values are mean ± SEM relative to the control group as 







Figure 2.5. Pituitary Hormone Levels.  
 
Pituitary response to GnRH stimulation was assessed in PKiRKO mice. Basal and Stimulated Serum 
LH (A) and FSH (B) were significantly increased in both control and PKiRKO groups following GnRH 
(200ng/kg) administration (n=6). GnRH stimulated LH was lower in PKiRKO than that in control male 
mice (n=6). (Basal LH=PKiRKO male: 1.08±0.44ng/mL, n=6 and control male: 1.79±0.86 ng/mL, n=6, 
P＞0.05) (Basal FSH=PKiRKO: 1.22±0.42 ng/mL, n=6 and control: 1.75±0.65 ng/mL, n=6) (GnRH 
Stimulated LH PKiRKO male: 3.40 ± 0.86 ng/mL, P=0.0002, n = 6 and GnRH Stimulated LH control 
male: 4.71±1.01 ng/mL, P=0.0003, n=6)Values are means±SEM relative to the control group as 
determined by a two tailed Students T-test. NS, not significant. .*P≤0.05;**P≤0.01;***P≤0.001. 








Figure 2.6. Receptor Expression in the Pituitary.   
 
 
 (A) GnRH receptor (Gnrhr) mRNA was significantly lower in PKiRKO male mice (n=8) than control 
male mice (n=8). (GnRHR; PKiRKO: 0.74±0.21, n=8 and control: 1.04 ±0.32, n=8, P＜0.05) (ER 
alpha; PKiRKO: 0.79±0.19, n=8 and control: 1.01±0.18 ng/mL, n=8. Values are mean ± SEM P＜0.05 







Figure 2.7. Calcium Assay of Primary Pituitaries.  
 
(A-F) Representative traces of calcium responses to agonist. A baseline measure of calcium (Ratio 
480/540) was recorded for 60 seconds before the addition of agonist. Calcium flux data was then 
recorded for an additional 840 seconds for a total observation time of 900 seconds. (Inset) Graph 
showing a “zoomed” in version of the traces, highlighting calcium dynamics 60-100 seconds after 
addition of the hormone. (G-L) Box plots of maximal Ca2+ 450/540 ratios from representative traces. 
Primary pituitary cells were treated with one dose of KP-10(10nM) –A,B,G,H, varying doses of GnRH 
(10, 30 and 100 nM)-C,D,I,J and varying doses of PACAP 38 (10, 50 and 100nM)-E,F,K,L.Values are 
means ±SEM *P≤0.05;**P≤0.01 as determined by a two tailed Students T-test or one way 









External anatomy and puberty assessment of (A) Males (B) Females.  











PKiRKO (A) Males and (B) Females exhibited no difference in anogenital distance compared to 
controls, and no obvious differences in gonadal physiology were seen. Values are means ±SEM as 










(A) GnRHR mRNA was not significantly different between control and PKiRKO male mice (n=8). (B) 
Esr1 mRNA levels were also not significantly different between control and PKiRKO female mice 
















(A) Representative sections of testes. Seminiferous tubules from a Control mouse (Left side images) 
and a PKiRKO mouse (Right side images) show all stages of spermatogenesis with numerous sperm. 
(B) Representative sections of ovaries. Representative sections from a Control ovary (Left side images) 
and a PKiRKO ovary (Right side images) showing follicles at all stages of development, including 
primary, preantral, antral, preovulatory follicles as well as corpora lutea. The number of corpora lutea 















(A) Body weight change over time was not different between PKiRKO and control female (n=15). (B) 
The weight of ovaries were not significantly different between PKiRKO and control female mice (n=6).   









Serum Testosterone (ng/dl) measured in male control and PKiRKO mice yielded no differences. Values 









(A) VO is an estrogen dependent process that serves as an external Kisspeptin receptor in the pituitary 
gonadotroph of male mice indicator of female puberty onset [21]. Another measure of puberty in female 
mice is the age at which first estrus is observed following VO.  No difference was observed at first 
estrus (35.6±2.4 [control] vs 33.3±3.2 [PKiRKO]) (B) Estrous cyclicity was evaluated. Vaginal smears 
were obtained daily over a period of 14 consecutive days in 6- to 11-week-old mice and cellular 
morphology examined under microscope to determine the stage of the estrous cycle. Control and 
PKiRKO groups both exhibited regular estrous cycles and did not differ from each other in percentage 
time spent at each cycle stage. Values are means ±SEM as determined by a two tailed Students T-
















(A) To quantitate the fertility of female PKiRKO mice relative to controls, 6 control and 6 PKiRKO 
female mice were housed with WT male mice for 14 consecutive days (3 females and 1 male per cage, 
total 4 cages) and then were separated. Females were followed for an additional week until they gave 
birth or were assessed to not be pregnant.  The same males were rotated between the 4 cages. (B) Total 
numbers of litters per female was not significantly different between control and PKiRKO mice during 
the 120 days. (C) After introduction with WT male, the day of first litter was recorded in both groups. 
(D) Number of pups per litter was also not significantly different between control and PKiRKO mice. 











(A) Basal serum LH values in PKiRKO mice were not significantly different in females relative to 
control mice. PKiRKO female: 0.57± 0.27ng/mL, n=6 and Control female: 0.49±0.22ng/mL, n=6, P＞
0.05. (B) Basal serum FSH values in PKiRKO mice were also not significantly different in females 
relative to Control female.  Values are means ±SEM as determined by a two tailed Students T-test 
















Double immunohistochemistry was performed for LHβ (immunofluorescence appears as white signal) 
and KISS1R (Nickel/DAB appears as black) Kisspeptin receptor in the pituitary gonadotroph of male 
mice from a representative male control mouse (left) and PKiRKO mouse (right). Red arrows point to 
KISS1R signal on LHβ expressing cells.  Green arrows point to KISS1R signal on non- LHβ expressing 
cells. LHβ; Rabbit-anti Rat, NIDDK-AFP 571292393, 1:5000.  KISS1R-Abcam, 1:3000. Magnification 










Ex Vivo pituitary cell culture. Pituitary cells from control male mice were treated with 30nM GnRH, 
for a duration of 30, 60 and 360 mins (n=4 wells per treatment). Secreted LH levels were then assessed 
from the cell media. Values are means ±SEM.*P≤0.05;***P≤0.001 as determined by a two tailed 
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The role of Estrogen and Kisspeptin action has been limited to its powerful effects on mammalian 
reproduction and development. However more evidence suggests that both Estrogen Receptor (ESR1) 
and Kisspeptin (KISS1) signaling exert powerful effects on organ systems such as the liver and the 
pancreas which are outside of the reproductive axis. There is now increasing recognition that ESR1 
regulation is critical for proper metabolic functions such as hepatic gluconeogenesis and lipogenesis, 
just to name a few. How both ESR1 and KISS1 signaling affect each other outside of the reproductive 
axis is not well understood. It has been previously shown that Estrogen is the main regulator of 
Hypothalamic Kiss1 expression in the Anteroventral periventricular nucleus (AVPV) as well as the 
Arcuate Nuclei. It was thus hypothesized that estrogen could affect hepatic KISS1 function as well. 
After using a real time polymerase chain reaction to first determine which KISS1 transcript variant is 
expressed in the liver, we then performed a chromatin immunoprecipitation to confirm the presence 
and binding of ESR1 to the hepatic Kiss1 gene. Furthermore, we identified functional Estrogen 
Response Elements (ERE’s) in the liver promoter regions of Kiss1, which can be modulated via the 
addition of 17β-Estradiol (E2). Using adeno-associated virus expressing CRE recombinase to ablate 
hepatic ESR1 in mice, we demonstrate that there was a significant negative correlation between ESR1 
expression and hepatic Kiss1 expression. In vitro studies further showed that addition of exogenous 
estrogen caused KISS1 protein levels to be dramatically reduced. We further examined the effect of E2 
on hepatic Kiss1 expression as well as Glucose6 Phosphatase (G6pase), Phosphoenolpyruvate 
carboxykinase (PCK1), Fatty Acid Synthase (Fas) and Acetyl-CoA carboxylase (Acc1). QPCR results 
showed that estrogen reduced mRNA expression of G6pase and PCK1, while the lipogenic genes Fas 
and Acc1 remained unchanged.  These studies lead us to believe that hepatic kisspeptin is responsive 
to estrogen in a similar manner as demonstrated in the brain. With the increasing advent usage of β-
Estradiol and kisspeptin as clinical therapeutic agents, their effects on metabolic parameters such as 








 In recent years, the rise of public health issues related to energy imbalances such as obesity, 
diabetes, and metabolic syndrome have created a great burden on health care systems worldwide. In 
particular, the rise in the development of type 2 diabetes, metabolic syndrome and polycystic ovary 
syndrome (PCOS), all of which are associated with reproductive dysfunction are of great interest to 
researchers. In this study we attempt to further elucidate the signals that link reproductive function to 
metabolic status, by implicating the role alpha estrogen receptor (ESR1) has on hepatic Kisspeptin 
(Kiss1) expression as well as on key gluconeogenic and lipogenic genes. 
Estrogen in its primary role as a female sex hormone is responsible for the regulation of both 
male and female reproductive development as well as secondary sex characteristics (Alonso & 
Rosenfield, 2002; Bakker, 2019) Estrogen exerts its effects on cells and tissues by binding to alpha-
estrogen receptor (ESR1 or beta-estrogen receptor (ESR2). It is important to note that ESR1, but not 
ESR2, is expressed in the liver (Matic et al., 2013). Following E2 binding to ESR1, this receptor 
complex then directly crosses into the nucleus of cells. Once inside the nucleus this estrogen and 
receptor complex binds to DNA nucleotide sequences known as estrogen response elements (ERE) to 
regulate gene transcriptions (Ayaz et al., 2019). It has been reported that the consensus ERE of 
5’GGTCAnnnTGCACC-3’ when placed upstream of ESR1 responsive genes, affected the 
responsiveness of that gene to 17β-Estradiol (E2) (Driscoll et al., 1998) . ESR1 binding studies found in 
genomic searches, show that a large amount of ERE’S contains half-site EREs or ½ERE: GGTCA. 
These half sites were used in this study to look at their regulation of the KISS1 gene. Outside of its 
effects on reproduction, awry E2 and ESR1 signaling has been implicated in metabolic issues including 
obesity (Della Torre et al., 2016 ; Stubbins, Holcomb, Hong, & Nunez, 2012) , metabolic dysfunction 






While originally discovered by the cancer field, when it was called metastin, kisspeptin (Kiss1) 
has been primarily studied by reproductive neuroendocrinologists due to its clear and powerful effects 
on the GnRH neuron. Kiss1-expressing neurons reside in the anteroventral periventricular nucleus 
(AVPV) and the arcuate nucleus (ARC) of the hypothalamus and send neuronal projections to the 
Gonadotropin Releasing Hormone (GnRH) neurons. KISS1, via signaling through its G-protein 
coupled receptor KISS1R, (Kisspeptin receptor, formerly GPR54) has been shown to be a key regulator 
of pubertal onset, homeostatic regulation of the HPG axis, and generation of the preovulatory LH surge 
(Irwig et al., 2004; Roa et al., 2006). The relationship between ESR1 and KISS1 signaling has been 
established in the brain. A pivotal study by Tomikawa et al showed that in the AVPV, the response of 
ESR1 to E2 treatment is to be recruited to the proximal promoter of the Kiss1 gene contributing to an 
increase in Kiss1 expression. While in the ARC, the ESR1 is dismissed from the proximal promoter in 
response to E2 leading to a decrease in Kiss1 expression (Song et al., 2014). Characterization of hepatic 
KISS1 and how E2 impacts hepatic Kiss1 expression is of focus in this study.  
The role and regulation of KISS1 from non- hypothalamic (peripheral) sources is only 
beginning to be understood. Tolson et al. showed that adult whole body Kiss1r KO females displayed 
dramatically higher BW, leptin levels, adiposity as well as were glucose intolerant (Tolson et al., 2014) 
. The observation that triggered interest in hepatic KISS1 was based on studies by our lab to identify 
hepatic signals mediating impaired insulin secretion in a state of constitutive hepatic activation of PKA 
signaling (L-Δ-prkar1a mice). A differential gene expression screen identified KISS1 as the most highly 
up-regulated gene in the liver that coded for a secreted protein (Song et al., 2014)  Interestingly humans 
with Type 2 Diabetes Mellitus also exhibit increased liver and plasma KISS1 levels (Song et al., 2014) 
. This finding has assisted to expand the role and responsibilities of peripheral KISS1 because it 
established that hepatic KISS1 is an integral component of an endocrine/metabolic regulatory loop that 
includes the pancreas, circulating glucose and the liver. (Song et al., 2014)  Our lab recently expanded 





mice including the finding that ESR1 inhibits gluconeogenesis by transcriptional inhibition of 
gluconeogenic genes Pck-1 and G6Pase (Song et al., 2014).  Given the well-established role of KISS1 
in regulating reproduction and our observations defining a role for hepatic KISS1 in regulating glucose 
stimulated insulin secretion, hepatic KISS1 could serve as a regulatory interface between the 
reproductive and metabolic systems in the body. Thus, its paramount to characterize the effect of 
estrogen on hepatic KISS1 as well as on liver function. 
Materials and Methods 
Animals 
Adult male and female mice (>2 months old) were used in this study. All animal studies were 
carried out in accordance with National Institutes of Health guidelines on animal care regulations and 
were approved by the Animal Care and Use Committee of the Johns Hopkins University. Mice were 
maintained under constant conditions of light and temperature (14: 10 h light⁄dark cycle; 22 C) and 
were fed a normal chow and water ad libitum. Male flEsr1 mice, harboring LoxP sites flanking exon 3 
of the Esr1 gene were injected, via the tail vein, with an adeno-associated virus expressing CRE 
recombinase or a control vector expressing GFP (AAV8.TBG.PI.-Cre.rBG, or 
AV8.TBG.PI.eGFP.WPRE-.bGH, respectively, both obtained from the Penn Vector Core). Seven days 
after tail injection, mice were sacrificed for further tissue processing. 
HepG2 Hepatocyte Cell Culture 
Hepg2 cells from a human male liver carcinoma were grown in Dulbecco's modified Eagle's 
medium (DMEM; Mediatech Inc., Herndon, VA, USA) supplemented with 10% fetal bovine serum 
(Hyclone, Logan, UT, USA) and 25 mM glucose, 5 mM l-glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin (Gibco, Grand Island, NY, USA). Cells were grown and maintained in an atmosphere 
with 5% CO2 at 37 °C. Cells were treated with 10nM of β-estradiol (Cayman Chemicals, Ann Arbor, 
USA) for 12 hours. 





DNA liver samples from male and female adult mice after feeding or fasting were subjected to 
PCR. In order to identify hepatic Kisspeptin transcripts, two microliters of DNA were mixed with 
DreamTaq Green PCR Master Mix (Thermo Scientific, Waltham, MA). as well as the Transcript 
Variant (TV) primers located in Supp Table 1.As previously described in (Novaira, Ng, Wolfe, & 
Radovick, 2009)  PCR conditions are as followed; initial denaturation at 94 °C for 4 min, followed by 
35 cycles of denaturation (94 °C, 30 s), annealing (59 °C, 30 s) and extension (72 °C, 45 s). The reaction 
was concluded with an extension for 10 min at 72 °C. The identities of amplified products were 
observed by agarose gel electrophoresis (1.5% agarose in buffer containing 40 mM Tris/acetate and 1 
mM EDTA) and visualized with ethidium bromide staining (0.5 μg/ml) under ultraviolet light. 
 Chromatin Immunoprecipitation analysis 
Chromatin immunoprecipitation (ChIP) was performed using ChIP-IT Express kit as indicated 
by the manufacturer (Active Motif, Carlsbad, CA). Liver samples from male mice which had either 
been kept on normal chow or fasted overnight were collected and subjected to 1%formaldehyde 
treatment. Using glycince, the fixation was halted. Following brief homogenization, the lysate was 
centrifuged at 1000 rpm for 5 min at 4°C. The nuclear pellet was then resuspended in lysis buffer and 
left on ice for 30 min. In order to fragment the DNA of these nuclear samples, a digital sonfier Model 
250 &450 (Danbury, Connecticut were used. Samples were sonicated on ice for 4 20 sec cycles with a 
60 second pause between each cycle. All samples were sonicated at 10% amplitude. The supernatant 
which contained the DNA fragments were them imunoprecipated using IgG ,CREB (cyclic AMP 
response element) ,and ESR1 antibodies as described in Supp. Table 3. Samples were then stored at -
80°C. The input DNA represents an aliquot of the sheared DNA which has not been 
immunoprecipitated, but reverse-cross-linked/DNA cleaned up. Finally primers for mouse Kiss1 
(spanning putative ERE and CRE-containing regions) were used for PCR. 





PCR was used on mouse liver tissues to amplify multiple fragments of the kisspeptin promoter. 
The primers used to amplify the different promoter regions are listed in Supp. Table 1. Added to the 
end of each fragment via PCR was a HIND III restriction enzyme site. The plasmid +180bp contains 
no ERE sites, +1102 contains 3 ERE half sites and +2956 contains 5 ERE half sites. Each fragment was 
then cloned into a pA3LUC reporter vector (LUC) using the common HIND III restriction site. The 
pCI Vector (Promega, Madison, WI)  contains the CMV immediate-early enhancer/promoter region 
and is constitutively expressed in mammalian cells, thus it was used a positive control. An empty 
pA3LUC reporter was used as a negative control. All plasmids were co- transfected with the pRL 
Renilla (Rluc) control reporter vector and were normalized to Rluc levels. Plasmids were next co- 
transfected into HepG2 cells in a 96 well plate transfection protocol via Lipofectamine 2000 (Thermo 
Scientific, Waltham, MA). Twenty four hours after transfection, cells were treated with or without 
10nM E2 for 12 hours.  Following manufacture instructions, the Dual Glo luciferase assay system 
(Promega, Madison, WI) was used to measure relative light output (RLU) directly from the wells. 
Immunofluorescence 
In order to confirm ESR1 knockdown via tail vein injection, liver tissue were harvested from 
injected mice. The liver was then fixed in 4% paraformaldehyde overnight. The following day the liver 
tissue is immersed in 30% sucrose for 24 hours at 4 °C. Finally, the liver tissue is embedded in Tissue-
Tek O.C.T (optimum cutting temperature) compound. Samples were next sent to the Johns Hopkins 
Reference Histology Reference Core for sectioning (5 um). As previously described, (Qiu et al., 2017a) 
immunofluorescence required the liver tissue to be treated with 1% Triton and blocked in 5% goat 
serum. Next the samples were immersed in 1% goat serum containing a 1:4000 dilution of anti-ESR1 
rabbit (Millipore, California, CA). Slides which contain the liver tissue were incubated with Alexa 
Fluor 594 goat anti-rabbit IgG (H + L) for 1 hour before nuclear counterstaining with DAPI and 
mounting (Vectashield Vector laboratories, Burlingame, CA). ESR1 fluorescence intensity as a 
measure of “protein density” was analyzed using ImageJ (National Institute of Health). 





Total RNA was extracted from a 6 well plate of HepG2 cells using the TRizol Reagent 
(Invitrogen, Carlsbad ,California, USA) following the manufacturer's instructions. Briefly, after a short 
incubation with the TRizol reagent, the cells were lysed using an homogenizer. The aqueous phase was 
separated by centrifugation after adding chloroform. The RNA was next precipitated as a pellet using 
isopropyl alcohol. The pellet is then washed with 75% ethanol, spun down again and finally 
resolubilized in nuclease-free water. RNA samples were quantified by using a Epoch 
spectrophotometer (BioTek Instruments, Winooski, VT). 1micorgram of RNA was converted to cDNA 
synthesized using the iScript cDNA Synthesis Kit (Bio-Rad).  
Quantitative Real-Time PCR (q-RT-PCR)  
Relative cDNA levels were determined using SYBR Green master mix Solution (Bio-
Rad,Hercules, CA, USA).  The genes of interest as labeled in Supp. Table 2.1 were examined by q-RT-
PCR using an I-Cycler quantitative PCR machine (Bio-Rad).  For each gene, 18S rRNA was used as a 
control. Reactions were carried out according to the manufacturer's instructions and conditions. Briefly, 
the first denaturing step is at 95 °C for 3 min, the second denaturing step was then 35 cycles at 95 °C 
for 10s. The annealing step required primer temperature ranges of 55–61 °C for 20s (depending on 
primer set). The final extension step was for 72 °C for 30 s. For each primer set, PCR efficiency was 
determined by measuring a 10-fold serial dilutions of cDNA and reactions with between 95% and 105% 
PCR efficiency were included in subsequent analyses. Relative differences in cDNA concentration 
between baseline and experimental conditions were then calculated using the comparative threshold 
cycle (Ct) method. Briefly, for each sample, a ΔCt was calculated to normalize for the internal control 
using the equation: ΔCt = Ct(gene) − Ct(18S). To obtain differences between experimental and control 
conditions, ΔΔCt was calculated: ΔCt(sample) − ΔCt(control). Relative mRNA levels were then 
calculated using the equation fold difference = 2ΔΔCt. 
Western Blot 
HepG2 cells were cultured in a 6 well plate and grown to confluency. Cells were then treated 





Technology, Danvers, MA) buffer supplemented with protease and phosphatase inhibitor (Thermo 
Scientific, Waltham, MA). Equal amounts of proteins(30µg) from the cell lysates were then separated 
via sodium dodecyl sulfate polyacrylamide gel electrophoresis (Thermo Scientific, Waltham, MA) and 
transferred to nitrocellulose membranes via a Trans Blot Turbo machine (Bio-Rad, Hercules, CA, USA 
).Next, the membranes were blocked with 5% nonfat milk in Tris-buffered saline containing 0.05% 
Tween 20 (TTBS) at room temperature, followed by an overnight incubation with the primary antibody 
anti-kisspeptin (Millipore, California, CA) at a 1:1000 dilution as shown in  (Table 3). The blot was 
then incubated in goat anti-rabbit (IgG-HRP conjugate) secondary antibody (Bio-Rad, Hercules, CA, 
USA) at room temperature for 2 hours. The blots were then washed and protein bands were detected 
using enhanced chemiluminescence (Perkin Elmer Life Sciences, Boston, MA). Densitometry was 
quantified using Image J (National Institutes of Health) 
Data and Statistical Analysis 
Each experiment in each experimental group was performed using either triplicate samples 
(Luc Assay or duplicate samples (q-RT-PCR)We used an unpaired Student's t-test to compare the 
mRNA levels of genes between groups treated with estradiol or vehicle. All results are expressed as 
mean ± SEM and p ≤ 0.05 assigned as significant using the GraphPad Prism 4 software (San Diego, 
CA, USA).   
Results 
Hepatic Kiss1 Gene and its transcript variant. 
The Kiss1 gene (Fig1A) consists of a number of splice variants that produce the same protein 
product(RW.ERROR - Unable to find reference:1460; RW.ERROR - Unable to find reference:1792) 
(Castellano, Wright, Ojeda, & Lomniczi, 2014) . However these published splice variants are from 
hypothalamic sources. In order to determine which transcript variant was found in the liver, we 
performed PCR using multiple transcript variant (TV) primers labeled in Table 1. Using male and 
female livers that had been fed or fasted as our DNA template, PCR was performed and ran on a 





Variant (TV) 4 and TV 4* around 600 base pairs. This leads us to believe that hepatic KISS1 expresses 
the full length KISS1 product identified as Ensembl Kiss 001 and 002.  
CREB AND ESR1 bind to hepatic Kiss1 Promoter 
Chromatin immuno-precipitation (ChIP) analysis of the upstream regions of Hepatic Kiss1 was 
used to explore ESR1 interaction with an E2 response element (ERE) in the proximal Kiss1 promoter. 
We used ChIP to explore ESR1 occupancy on the ERE in the Kiss1 promoter (Figure 3.2) in the liver 
of mice fasted overnight, or control mice fed ad libitum. As previously reported (Castellano et al., 
2014), glucagon induces CREB occupancy on a CREB response element (CRE) in the Kiss1 promoter 
in response to a fast. Supporting the observation that Esr1 expression was lower in fasted and DIO 
mice, we observed a dismissal of ESR1 from the Kiss1 promoter in response to fasting suggesting that 
ESR1 serves to repress Kiss1 expression in the liver.  
Estrogen affects Kiss1 promoter activity 
To explore the protein-DNA interactions that occur within the Kiss1 promoter and the role of 
these interactions in targeting hepatic Kiss1 gene expression we created fragments of hepatic kisspeptin 
promoter (+180, +1102, and +2956) fused to the luciferase reporter gene. Up to 5 ERE’s on the 
Kisspeptin promoter are found on the +2956 plasmid and 3 ERE’s on the 1102 promoter, while the 
shortest fragment +180 promoter contains no ERE’s and thus was utilized as a negative control.   After 
transfections of plasmids and treatment of HepG2 cells with 10nM of β-Estradiol treatment for 12 
hours, results show E2 caused a significant increase in relative light output only in the +2956 Kisspeptin 
promoter plasmid (Fig 3). There was no significant change in the +180 and +1102 group. The positive 
control and negative controls behaved as expected as a high RLU output was detected in the +/- E2 pCI 
group, and a low output in the empty LUC group, respectively.  
Negative correlation between ESR1 expression and hepatic Kiss1 expression 
In order to determine the effect of ESR1 on hepatic Kiss1 expression, we deleted ESR1 in the 





sites flanking exon 3 of the Esr1 gene. These mice were tail injected, with either an adeno-associated 
virus expressing CRE recombinase (called LERKO mice going forward) or a control vector expressing 
GFP. In order to quantify the knockdown of hepatic ESR1 expression mice were sacrificed and liver 
harvested for histological analysis. LERKO mice exhibited nearly complete disruption of Esr1 mRNA 
levels and ESR1 protein levels compared to GFP injected controls as shown in Figure 3.4 B and 
quantified in Figure 3.4 A and C.  LERKO mice were found to have a dramatic increase in Kiss1 mRNA 
levels which was highly inversely correlated with Esr1 mRNA levels (Fig 5a and b), and a nearly 30% 
increase in serum KISS1 (Fig 3. 5c) 
E2 reduces kiss1 protein and mRNA levels in vitro 
To further validate the negative correlation between ESR1 and Kiss1 expression we directly 
treated HepG2 cells with exogenous E2 and looked at effects on both protein (Fig 3.6 A & B) and 
mRNA levels (Fig 3.6 C). We show that both 1nM and 10nM were effective in significantly reducing 
KISS1 expression in hepatocytes. Normalizing with actin protein levels, KISS1 expression levels are 
quantified in Figure 3.6 B. Furthermore, qPCR results show that Kiss1 mRNA levels were significantly 
reduced when HepG2 cells were treated with 10nM of E2 for (Fig 3.6 C). 
E2 reduces hepatic gluconeogenic genes and leaves lipogenic genes unchanged 
In a novel study using primary hepatocytes from LERKO mice, Qui et al (Qiu et al., 2017) 
showed that E2 treatment lead to the downregulation of the major gluconeogenic genes PCK1 and 
G6Pase as well as de novo lipogenic genes FAS and ACC1. In order to validate these effects in an in 
vitro cell model (HepG2), we also measured mRNA expression changes in the aforementioned genes. 
Figure 3.7 A and B show that HepG2 gluconeogenic genes were both significantly reduced by 12 hours 
of E2 treatment. Surprisingly we did not see decreases in de novo lipogenesis in HepG2 cells. Rather 
we saw no significant changes in FAS (Fig 3.7 C) or ACC1 (Fig 3.7 D). Possible reasons for this 








Estrogens have been shown concussively to control the development and physiology of 
mammals. While the role and study of estrogen signaling has been limited to the development and 
function of the female reproductive system, there is mounting evidence that they also play crucial roles 
in male reproduction and in tissues outside of the reproductive axis such as the liver (Qiu et al., 2017b), 
adipose tissue, cardiovascular system and adipose tissue  (Couse & Korach, 1999; Ciocca & Roig, 1995). 
Of focus in this study is the effect of E2 on the newly discovered hepatic hormone KISS1. We have 
recently reported that the liver is a source of circulating KISS1 and that hepatic KISS1 serves to regulate 
glucose stimulated insulin secretion (Song et al., 2014)  This profound finding leads to a plethora of 
questions addressing the regulation of hepatic KISS1. Hepatic KISS1 and its role beyond a paracrine 
hormone from the liver are just beginning to be understood.  
Although several studies have looked at the regulation of Kiss1 expression (Tomikawa et al., 
2012; Castellano et al., 2014; Mueller et al., 2011) , these studies have utilized brain and reproductive 
tissues to profile Kiss1, thus leaving knowledge of the transcript variant expressed in the liver unknown. 
Using liver samples from both male and female fed and fasted mice we conducted PCR to identify 
which KISS1 transcript is expressed in the liver. As noted in Table 1, we utilized publicly available 
NCBI and Ensembl Kiss1 transcript primers to identify our liver Kiss1. Our results as shown in Figure 
3.1 B are that hepatic KISS1 expresses the full length KISS1 product identified as Ensembl Kiss 001 
(TV 4) and 002(TV4*). Interestingly other predicted transcript variants such as the shorter 202 (TV 1) 
and the longer 201 (C.V.) were unable to be detected via PCR. It was noted that male PCR products in 
Figure 3.1 B showed several bands in there lanes, which were not seen in the PCR product bands of 
female hepatic liver samples. This difference in Kiss1 PCR products between male and female livers 
could be indicative of a sexual dichotomy in Kiss1 hepatic splice variants. However, taken together we 





The analysis of Kiss1 expression in mouse is complicated by reports of at least five different 
transcript variants expressed under the control of different promoters (Figure 3.1 A). While all the 
transcripts produce identical KISS1 protein, differences in promoter regulatory elements could 
contribute to tissue specific differences in regulated Kiss1 expression. For example, CREB regulation 
of Kiss1 in the brain is mediated by a CRE in the promoter of transcript variants 001 and 002 (Song et 
al., 2014) and ESR1 regulates hypothalamic expression of transcript variants 201 and 202 (Tomikawa 
et al., 2012). A similar finding was reported for expression of Kiss1 in the rat (Castellano et al., 2014). 
We observed a reduction of ESR1 on the Kiss1 promoter in response to fasting. This effect was reversed 
after feeding. This evidence begins to suggest that ESR1 may repress Kiss1 expression in the liver 
alluding to the fact that hepatic Kiss1 is regulated by both metabolic status and reproductive status, and 
may in turn regulate metabolic and reproductive function. 
To further understand the transcriptional regulation of hepatic Kiss1, in vivo epigenetic 
analyses of hepatic Kiss1 promoter region was conducted. Work from our group (Song et al., 2014)  has 
shown that one of the known promoter regions of Kiss1 contains a cyclic AMP response element (CRE), 
suggested to mediate glucagon regulation of Kiss1, while another promoter contains an estrogen 
response element (ERE). The CRE and ERE in the Kiss1 promoters are found in the proximal regions 
before Exon 2 and 3 respectively (Figure 3.1 A).  Promoter reporter vectors were developed by inserting 
promoter fragments into the PA3LUC reporter vector (+180, +1102, and +2956).  All reporter 
fragments, but the +180bp promoter fragment include an ERE. Transfections were performed in the 
presence or absence of E2 to identify E2 responsive regions specific to hepatocytes (HepG2) as assessed 
by luciferase activity. As shown in Figure 3.3, after normalization to Rluc levels, the +2956 KissProm 
vector yielded the most significant increase in RLU values after addition of 10nM of E2. This suggests 
that during the fed state (DMEM containing serum), the addition of exogenous E2 was able to modulate 





The production of the LERKO mice gave us clear evidence that E2 was indeed regulating 
hepatic Kiss1 expression. After ablating hepatic ESR1 via a viral tail vain injection targeting liver 
ESR1, we showed that both Kiss1 mRNA and serum KISS1 levels were significantly increased (Figure 
3.5. This increase in serum KISS1 was associated with a ~2-fold attenuation of glucose stimulated 
insulin secretion (Ratio of glucose stimulated insulin secretion to basal, AAV8-GFP, 12.27 +/- 2.9, 
AAV8-CRE, 6.24 +/-1/46, p<0.05). These data support a negative regulation of Kiss1 expression by 
ESR1.Contrary to both the ARC and AVPV, where ESR1 interaction with the Kiss1 promoter up-
regulates Kiss1 expression; E2 increasing promoter occupancy by ESR1 in the AVPV and decreasing 
promoter occupancy by ESR1 in the ARC (Tomikawa et al., 2012; Goto et al., 2015). Because the 
presence of ESR1 serves to repress Kiss1 expression we believed that direct treatment of the liver with 
E2 should also directly cause Kiss1 expression to decrease. Figures 3. 5 A, B and C show the effect of 
E2 on hepatic KISS1 and Kiss1 mRNA levels. The dramatic decrease of hepatic KISS1 post E2 
treatment further implicates further how reproductive status could affect metabolism.  
The liver plays a crucial role in glucose and insulin homeostasis. Not only does the liver itself 
produce hepatic glucose, but it also sends cues to other organs i.e KISS1 to the pancreas, in order to 
modulate glucose production. It has been shown that estrogen deficiency contributes to the development 
of hyperglycemia and type 2 diabetes (Gallagher et al., 2007).  Previous studies in which ESR1 has 
been deleted show that in both male and female ESR1 knockout mice are obese with both insulin 
resistance and impaired glucose tolerance present (Heine, Taylor, Iwamoto, Lubahn, & Cooke, 2000). 
Our data contributes to those findings as we found that the key gluconeogenic enzymes G6Pase and 
PEPCK are reduced in the presence of E2 (Figure 3.7 A and B).  The gluconeogenic enzymes G6Pase 
and PEPCK do not undergo posttranslational modifications and are regulated by transcriptional activity 
(Jitrapakdee, 2012) . We show that E2 directly downregulates mRNA expression of G6Pase and 
PEPCK possibly by directly binding to the ERE’s found on their promoters as suggested by Qui et al 





promoter). More epigenetic analyses such as histone and chromatin changes in the proximal promoter 
are needed to properly assess ESR1 regulation of hepatic Kiss1, Pck1, and G6p1 gene expression. We 
saw no significant changes in the de no novo lipogenic genes FAS (Figure 3.7 C) or ACC1 (Figure 3.7 
D). It was previously suggested that E2 treatment of primary hepatocytes caused a decrease in the 
aforementioned genes (Qiu et al., 2017) . Although we see a slight decrease in ACC1 mRNA levels, the 
decrease was not significant. This difference could be due to the models in which are being used, a 
primary hepatocytes versus a hepatic cell line. The HepG2 cell line being the most commonly used 
liver cancer cell line in metabolic studies was chosen for this study. However other hepatic cell lines 
such as Hep3B, Huh7 and HA22VT could possibly be treated with E2 and yield results closer to the 
published primary hepatocyte lipogenesis data.  
Given the well-established role of E2/KISS1 in regulating reproduction, our previous 
observations defining a role for hepatic KISS1 in regulating insulin secretion, and now our finding of 
E2 directly affecting KISS1 expression; this evidence leads us to believe that hepatic KISS1 could serve 
as a mediator of signals and cues between the reproductive and metabolic systems in the body. 
Kisspeptin was only discovered in 2003; therefore, there are still numerous advancements and 
contributions to be made in the study of its action and regulation. An understanding of the tissue specific 
regulation of the hepatic KISS1 could contribute to the development of novel therapeutics that would 
target hepatic KISS1 effects regulating metabolism, while sparing precious and critical neuroendocrine 
KISS1 function. Additionally, comprehending ways in which reproductive status can impact energy 
metabolism could broaden society’s understanding of metabolic changes that occur during puberty or 
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 A.) Transcript variants of mouse Kiss1 are expressed from two different first exons, 001 (referred to 
as transcript X3, XM_006529681, on NCBI) and 002 (referred to as X4, XM_006529682, on NCBI) 
are regulated by CREB at a CRE and 201 (referred to as X2, XM_006529680, on NCBI) and X1 
(XM_006529679, not listed at Ensembl) are regulated by ESR1 at an ERE. X1 and X3 include a larger 
2ndexon (including the shaded region) and X2 and X4 include a smaller 2nd exon. The transcriptional 
start site for Kiss1X3and X4 is located in an exon of the Golt1a gene. B.) PCR was performed on 
fed/fasted male and female liver samples using primer pairs as labeled in Supp. Table 1. Transcript 















ChIP results showing increased occupancy by CREB at the CRE, and reduced ESR1 occupancy at the 
ERE in the Kiss1 promoter following an overnight fast in male mice. IgG used as a negative control. 










 Luciferase (LUC) expression in Kiss1Prom-LUC reporter plasmids. The pattern of LUC/Rluc 
expression measured as relative light units (RLU) is a reflection of Kiss1 promoter activity in the 
presence of 10nM of exogenous E2. pCI=positive control,EmptyPa3LUC (no promoter 
insert),+180bp(no ERE’s), +1102bp(3 ERE’s), +2956bp(5 ERE’s). Graphed as means ± SEM of RLU. 
(Three independent experiments were conducted using triplicate samples-Two Tailed-Student Test 












 A) Relative mRNA levels of Esr1 in livers from control (black bar) and CRE (red bar) injected male 
mice. B) Liver immunohistochemistry for ESR1 protein (Red-Cy5 staining). Left is liver section from 
GFP injected control, to the right is liver section from CRE injected mouse. C) Image J analysis 
calculated relative levels of ESR1 Ab labeled with Cy5 in GFP (Black bar) and CRE (red bar) injected 
mice. For A and C, n=4-6 mice, ** indicates p<0.01. (Three independent experiments were conducted 









A) GFP injected control mice=black. CRE injected LERKO mice=red. Liver Kiss1 mRNA, n=4-6 mice, 
* indicates p<0.05. B) Correlation of Esr1 and Kiss1 mRNA in the. Pearson correlation analysis. C) 
Serum KISS1 levels as measured by RIA. (Three independent experiments were conducted using 










 A.) Protein expression of HepG2 KISS1 and Actin after treatment with 1 and 10nM of E2. B.) 
Quantification of the KISS1 protein band densities. (n=2 bands per treatment). C.) QPCR results of 

















A.) Effect of E2 treatment on the mRNA levels of the gluconeogenic genes G6pase and Pck1 as well 
as the lipogenic genes Fas and ACC1 are shown. B.) mRNA levels of Kiss1 in response to estradiol 
treatment. n=4 wells. The data are expressed as the means ± SD, *p<0.05, vehicle vs 10nM estradiol.  
(Three independent experiments were conducted using triplicate samples-Two Tailed-Student Test 
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 Low-Dose DHT’s effects on glucose and energy metabolism are ameliorated by central 
























 Hyperandrogenima (HA) and Polycystic Ovarian Syndrome (PCOS) are a result of the 
imbalance of androgen secretion. Due to the international scope of its effects on reproductive 
age women, mechanisms of HA signaling have become a key area of study. The classical 
defects caused by both HA and PCOS include but are not limited to the following; 
hyperandrogenemia, oligo/anovulation, polycystic ovaries, diabetes mellitus, hypersecretion 
of luteinizing hormone (LH), and hyperlipidemia. Using a low dose treatment of 
dihydrotestorsteorene (DHT) we are able to recapitulate impaired glucose homeostasis and 
hyperinsulinemia in female mice. Findings from clinical observation, animal models and 
pharmacological studies have provided strong evidence to support the direct involvement of 
androgens and androgen receptors (AR) in DHT induced metabolic and reproductive 
dysfunction .We and other labs have hypothesized that the androgen receptor (AR) might be a 
possible target for unraveling HA induced metabolic defects. In this study, we specifically 
ablated the AR in the central nervous system (CNS), creating a mice referred to as SynARKO 
(Synapsin Androgen Receptor Knockout). Characterization of the SynARKO mice included 
reproductive tests, hormonal assays, and metabolic tests. SynARKO mice were assessed by the 
ages of vaginal opening and first estrus, where no differences were seen in comparison to WT 
mice.  There was also no difference in cyclicity and fertility between Control and SynARKO 
mice. When challenged with a bolus of glucose via a glucose tolerance test (GTT), female mice 
of Control and SynARKO implanted with DHT (3 months of DHT insertion) that are younger 
than five months old displayed impaired blood glucose tolerance as Con-DHT when compared 
to Con-no DHT mice. However, once these mice older than seven months with DHT (5 months 
of DHT insertion), SynARKO-DHT mice showed improved GTT compared to those of Con-





by overall improved metabolic rates including improved rates of oxygen intake and carbon 
dioxide release. Furthermore, differences in energy expenditure were observed between 
Control-DHT and SynARKO-DHT mice.  The improvements in both GTT and metabolic rates 
by deleting AR in the CNS implicate that the CNS-AR has a crucial role in metabolic 
homeostasis of middle-aged female mice with HA.  
Introduction 
Hyperandrogenism is one of the diagnostic criteria of PCOS, along with anovulation 
and morphologic polycystic ovaries. According to the Rotterdam criteria, a patient with two of 
the three criteria can be diagnosed with the syndrome (Rotterdam ESHRE/ASRM-Sponsored 
PCOS Consensus Workshop Group, 2004). In order to model PCOS effects in animals, several 
animal models have been produced in literature. These models include high dose DHT 
(Caldwell, A. S. et al., 2014; van Houten et al., 2012), letrozole treatment (Kauffman et al., 
2015; Kelley, Skarra, Rivera, & Thackray, 2016), Dehydroepiandrosterone (DHEA) (Elia et 
al., 2006; Solano, Sander, Ho, Motta, & Arck, 2011) as well as prenatal androgen exposure 
(Demissie et al., 2008; Roland, Nunemaker, Keller, & Moenter, 2010). However, these models 
showed reproductive dysfunction but were also associated with obesity. This is problematic 
because obese female rodents and women have higher circulating testosterone levels and 
impaired fertility and metabolic dysfunction (Brothers et al., 2010; De Leo et al., 1998; 
Delemarre-van de Waal et al., 2002). Consequently, it is not possible to determine whether the 
phenotype is caused by the androgen excess or obesity. Further, serum androgen levels in 
women with PCOS or corrected congenital adrenal hyperplasia (CAH) are approximately 2-3 
fold higher than in normal women (van Houten et al., 2012; Caldwell et al., 2017; Kamel & 





models, we created an adult mouse model with impaired reproductive and metabolic 
dysfunction by chronic DHT exposure from insertion of a pellet with 4mm length of crystal 
DHT powder (total length of pellet is 8mm).  This model produces serum DHT levels that are 
about two fold higher (referred to as 2xDHT) than that of control mice without DHT treatment 
(Wu et al., 2014).  These mice displayed normal body mass/composition and 
pathophysiological serum androgen levels (twofold that of controls). With this new low dose 
DHT model, Andrisse et al (Andrisse et al., 2017) demonstrated that hepatic AR with HA 
contributes hepatic insulin resistance and increased hepatic gluconeogenesis.  
The androgen receptor is a member of the nuclear receptor subfamily and mediates the 
action of testosterone and dihydrotestosterone. Because of their steroidal nature, androgens can 
directly bind the genes and become transcription factors (Mooradian, Morley, & Korenman, 
1987). AR contains both an N & C-terminal regulatory domain (Jenster, van der Korput, 
Trapman, & Brinkmann, 1995), a DNA binding domain (DBD), a hinge region, and a ligand 
binding domain (LBD) (Saporita et al., 2003). AR signaling has been shown to alter an array 
of genes including but not limited to; FoxO1 (Andrisse et al., 2017a),CREB (Aarnisalo, 
Palvimo, & Janne, 1998; Kim, Jia, Stallcup, & Coetzee, 2005), BRCA1(Yeh et al., 2000), 
LH/FSHβ (Dalkin et al., 1992; Thackray, McGillivray, & Mellon, 2006),SIRT1 (Fu et al., 
2006),p300 (Fu et al., 2000) and SRY (Yuan, Lu, Li, & Balk, 2001) just to name a few.  The 
role of androgens in male fertility is known and well-studied (Abbott, Padmanabhan, & 
Dumesic, 2006), but the role in female fertility is under investigation.  A global knockout in 
females was reported by Hu and colleagues in 2004 and revealed that AR knockout mice have 
fewer corpa lutea, subfertility, and longer estrous cycles (Hu et al., 2004). Subsequent studies 





dependent follicle loss (Shiina et al., 2006).  In addition, a granulosa cell specific deletion of 
AR yielded the same phenotype of reproductive failure that is similar to that the effect of an 
AR global knockout (Sen & Hammes, 2010). The transplantation of WT ovaries into global 
KO mice did not completely restore fertility and suggested that AR causes a defect in the 
system that cannot be rescued with only a transplant.  These results taken together indicate that 
AR is regulating fertility at another level, most likely the pituitary or hypothalamus. 
To begin to assess the role of AR in the neuroendocrine system with or without HA, 
Wu et al. created a pituitary specific androgen receptor knockout to explore the role of AR in 
the pituitary (Wu et al., 2014; Wang et al., 2019).  Deletion of AR in gonadotropes ameliorated 
DHT induced infertility. These results taken together indicate that AR is regulating fertility 
may act in multiples levels. 
HA in the brain has been understudied with few studies implicating AR action in the 
brain. One particular study found that the neuropeptide Kisspeptin is mediated by AR and may 
be important in fertility.  Rats implanted with DHT for 90 days had significantly less Kiss1 
expressing cells in their Arcuate nuclei neuronal population, the authors hypothesized that the 
inhibition of Kisspeptin expression is responsible for the decreased LH and FSH surge (Iwata, 
Kunimura, Matsumoto, & Ozawa, 2017).  Caldwell et al. used brain AR knockout female mice 
as well as a DHT-induced PCOS model to determine how androgens act within the brain during 
the development of PCOS. The conclusion was that brain-specific AR signaling with HA led 
to key PCOS phenotypes including dysfunctional ovulation and polycystic ovaries, as well as 
some metabolic problems (Caldwell, A. S. L. et al., 2017). To date, only one other group has 
attempted to delete AR in the central nervous system. Using male mice, Chang et al, found that 





insulin resistance, lipid accumulation, and visceral adiposity (Yu et al., 2013). This describes 
effects of AR function in male mice, AR function in the CNS of female mice with HA is yet 
to be examined. 
 The regulation of energy metabolism and reproduction is complex, involving multiple 
tissues, hormones and energy containing substrates. In this study we aim to directly investigate 
the role of central nervous AR in the hyperandrogenemia-induced reproductive and metabolic 
dysfunction.  
Materials and Methods 
Generation and genotyping of SynARKO mice 
  The central nervous system (CNS) specific knockout was created using Cre 
recombinase under the control of the Synapsin promoter, referred to as SynARKO. The 
knockout is generated by mating a floxed AR mouse (acquired through EMMA, The European 
Mouse Mutant Archive, deposited by Guido Verhoeven) with a Synapsin Cre mouse (Jackson 
Laboratories). To obtain heterozygous females, a Synapsin Cre female (SynCre+/-; AR wt/wt) 
was mated with a floxed AR male (AR fl/y; Cre-). To create the SynARKO mouse (AR fl/fl; 
cre+/-), a heterozygous female (fl/wt; SynCre+/-) was mated with a male (AR fl/y; cre-). 
Littermates were used as controls if they were female and had the appropriate genotypes (AR 
fl/wt; cre-) or (AR fl/fl; cre-). Genomic DNA isolation and primers (M28/M29) were used to 
detect the AR gene. Cre (M28) primer Forward: GTTTACGCTACCCCGTGCTC and (M29) 
Reverse: CATCTTCAGGTTCTGCGGGAAACC. All procedures were performed with the 






Knockout and control mice were sacrificed, followed by tissue extraction of 
hypothalamus, pituitary, ovary, and liver. All samples were immediately frozen in liquid N2. 
Extraction of protein from tissues, measurements of protein concentration, and western blot 
analysis of protein expression were performed as described previously (Wu, Divall, 
Wondisford, & Wolfe, 2012).AR antibody (N-20) and actin antibodies were purchased from 
Santa Cruz Biotechnology.  
Hyperandrogenemic mouse model 
Female mice were kept with normal chow and water ad libitum under a 14-h/10-h 
light/dark cycle.  Creation of the DHT pellets followed previously described procedures 
(Andrisse et al., 2017; Xue et al., 2018). Dow Corning Silastic tubing (0.04 inch (1mm) inner 
diameter & 0.085 inch (2.15mm) outer diameter; Cat# 1118915D, Fisher Scientific, Hampton, 
NH) were filled with 4mm lengths of DHT or no-DHT, and then sealed with medical adhesive 
silicone (Factor II, Lakeside, AZ). Pellets were incubated in saline for 24 hours at 37°C for 
equilibration before insertion. Two months old female mice were subcutaneously implanted 
with a 4mm pellet with or without DHT.  Pellets were replaced monthly to maintain a constant 
level of androgen excess. Experiments are conducted with hyperandrogenemic mice after 14 
days implantation. 
Assessment of puberty, estrous cyclicity, and reproductive performance in SynARKO 
females 
Puberty was assessed starting on the 21st day of age by visual inspection of vaginal 
opening.  After vaginal opening, the date of first estrous was determined by vaginal cytology 





cytology on SynARKO mice and -control littermates.  Reproductive performance was assessed 
as previously described (Brothers et al., 2010). Briefly, each of four SynARKO females and 
four control females was mated with a proven fertile male (ARfl/y; Cre-) mouse for 90 days. 
The number of litters and the number of pups per litter were observed and documented. 
Quantitative Real-Time PCR 
Tissue from SynARKO and control mice was homogenized and RNA was collected 
using Trizol extraction (Invitrogen, Carlsbad, California, USA).  RNA from AVPV, arcuate, 
hypothalamus, liver, ovary, muscle, and adipose tissue was reverse transcribed to cDNA. 
mRNA levels of genes of interest were measured on an I-Cycler quantitative PCR machine 
(Bio-Rad) using iQSYBR green reagent according to the manufacturer’s protocol. 18S was 
used as an internal control. The genes tested were: AR (Androgen Receptor), GPR54 (G-
Protein Coupled Receptor 54), KISS1 (KiSS-1 Metastasis-Suppressor). 
Histology 
Ovaries were dissected from SynARKO and control mice.  Each sample was either 
snap frozen by liquid nitrogen and stored at -80 C or fixed in 10% formalin buffer.  The tissues 
were submitted to the Johns Hopkins Histology Core Facility. The facility embedded the 
tissues in paraffin and sectioned them at 5 um thickness. Every 10th section was collected and 
stained with hematoxylin and eosin (H&E). Ovaries were examined and follicles were counted 






Blood was collected from the mandibular vein via cheek puncture. Vaginal smear was 
used to determine the stage of the estrus cycle of the mouse at the time of the blood draw. 
Blood was centrifuged at 12,400 rcf for 15 min. The serum containing supernatant was stored 
at -80 C. 
Hormone Assays 
Morning levels (9-10 am) of LH and FSH from serum of mice at proestrus, estrus, and 
metestrus/diestrus were measured by luminex assay (Kit RPT-86K; EMD Millipore, Germany) 
Serum levels of estradiol were measured using an estradiol ELISA (Mouse E2 Elisa, 
Calbiotech,). Each estrous cycle stage was tested for estradiol levels. Serum testosterone levels 
were measured using testosterone ELISA (Total T Elisa, Calbiotech). LH levels were also 
tested by shipping 5ul to University of Virginia Ligand Assay Core (Charlottesville, Virginia).   
MRI Body Composition Measurement 
Body composition of the wild type and SynARKO mice was measured as described 
previously (Ma et al., 2017).  Briefly, each mouse was loaded into the EchoMRI (EchoMedical 
Systems, USA) system to measure the fat, lean, and water mass. All measurements were made 
in the morning.  
Body weight analysis 
Mice were weighed every 7 days starting from day 14 through day 70. The cycling 






After being allowed to acclimate to respiratory chambers for one day, mice were then 
monitored for 48 hours. Mice were kept under a 12-h light/ 12-dark cycle in a Comprehensive 
Lab Animal Monitoring System (CLAMS) (Columbus Instruments, Columbus, OH).Data 
collected included rates of oxygen consumption, carbon dioxide production, respiratory 
exchange, heat, activity, body weight, and food intake.  
Statistical Analysis 
Each experiment was performed using either triplicate samples or duplicate samples 
(q-RT-PCR). We used an unpaired Student's t-test to compare the mRNA levels of genes 
between groups treated with low dose DHT or vehicle. All results are expressed as mean ± 
SEM and p ≤ 0.05 assigned as significant using the GraphPad Prism 4 software (San Diego, 
CA, USA).   
Results 
Generation of SynARKO Mice 
As diagrammed in Figure 4.1, we utilized cre lox recombinase technology in order to 
ablate AR expression specifically in central nervous systems expressing Synapsin Cre. AR fl/fl 
mice were generated by mating heterozygous female mouse (ARfl/wt; α Cre+/-) with male 
mouse (AR fl/ Y; α Cre-/-). Disrupted AR expression was determined by quantitative real-
timePCR and western blot. AR mRNA levels were significantly reduced up to roughly 75% in 
hypothalamus of SynARKO mice compared with that in their control littermates. Other tissues 
such as the pituitary, ovary, and liver have similar levels of AR expression (Figure 4.2 A). 
Expression of AR is reduced in the SynARKO mice, but not abolished. AR protein levels were 





reduced in hypothalamus of SynARKO mice compared with those in control mice; there was 
no change in AR protein expression levels in pituitary, ovary, and liver from control and 
SynARKO littermates (Figure 4.2), 
SynARKO mice display same time of puberty and first estrus and similar pattern of 
estrous cyclicity 
Vaginal opening and first estrus are two indicators of female puberty onset. Daily 
vaginal smears were obtained after vaginal opening to identify the age of first estrus. There 
was no significant difference in either vaginal opening or first estrus between the control and 
SynARKO groups (Figure 4.3 A). To assess the ongoing reproductive cyclicity of the female 
mice, vaginal cytology was analyzed from adult female mice for 16 consecutive days; control 
and SynARKO groups both exhibited regular estrous cycles (Figure 4.3 B,C). Although AR 
knocked out in CNS cells did not affect estrous cyclicity or fertility under normal physiological 
androgen level, we investigated if AR in CNS cells plays any role in hyperandrogenemia-
induced acyclicity. We treated mice with 4-mm DHT pellets to produce serum androgen levels 
that mimic those in human hyperandrogenic phenotypes. We show that knocking out CNS AR 
does not rescue the acyclicity seen in DHT treated control mice. SynARKO-DHT and Con-
DHT mice were both acyclic and spent comparable amounts of time in each estrous stage 
(Figure 4.3). 
SynARKO female mice exhibited no difference in the numbers of litters compared to 
controls 
Fertility was examined in a continuous mating protocol in control and SynARKO mice. 





total number of litters were recorded (Figure 4.4 A). During the 90-day mating period, there 
was no significant difference in the number of litters and pups between Control and SynARKO 
mice (Figure 4.4 B and C). 
Hormone Levels are not altered in SynARKO mice 
In order to determine if key hormone levels are altered in SynARKO mice, blood 
samples were collected in order to measure T, E2, LH, and FSH levels from adult female mice. 
Compared to control, there was no significant difference of T levels in SynARKO (Figure 4.5 
A ,B) and E2 (Figure 4.5 C,D) levels at different cyclic stages or combined. During different 
estrous stages of the female mice cycle, LH (Figure 4.6 A) and FSH (Figure 4.6 B) levels were 
ascertained. While no difference in LH levels were seen between Control and SynARKO mice 
during different stages, FSH levels were similar only during the metestrus and proestrus stage. 
During the estrus stage, FSH levels were higher in Control female mice than in SynARKO. 
Effect of CNS AR deletion on body weight and whole body composition 
The central nervous system innervates the entire anatomy of mammals. Thus changes 
to the CNS physiology of a mouse could yield changes to the whole animal physiology. Total 
body weight was not different between Control and SynARKO female mice (Table 4.1). 
EchoMRI was conducted to measure total percent of fat and water. Treatment of Control and 
SynARKO female mice with DHT did not alter mice body composition (Table 4.1).  
SynARKO mice with DHT have improved glucose tolerance compared to Control-DHT 
Metabolic tests were conducted in order to determine the effect of CNS AR deletion on 
glucose homeostasis. At 4 months old and 2 months of DHT insertion a GTT and ITT protocol 





same tests were repeated (Figure 4.7 E-H).  After a 16 hour fast, female mice were injected 
with a bolus of glucose (2g/kg body weight) and their blood glucose levels were tracked for 
120 minutes. At 4 months old (2 months of DHT insertion), SynARKO-DHT showed similar 
glucose tolerance compared to Control-DHT. (Figure 4.7 A, B). As expected blood glucose 
levels were significantly higher in DHT treated Control mice than untreated mice (Figure 4.7 
A, B). Insulin resistance caused by HA is clearly evident in Figure 4.7 C and D. Both 
SynARKO-DHT and Con-DHT female mice serum glucose levels remained significantly 
higher over time in comparison to Con-no DHT after an injection of insulin (0.5Unit/kg).  At 
6-7 months old (4-5 months of DHT insertion) SynARKO-DHT showed improved glucose 
tolerance compared to Con-DHT (Figure 4.7 E, F). DHT induced insulin resistance was not 
corrected in SynARKO mice either at the early or later time points we performed the ITT 
(Figure 4.7 E,F). 
DHT treated SynARKO mice have similar energy expenditure to untreated control mice 
In order to determine the impact of CNS AR on whole body energy expenditure and 
other metabolic parameters, we performed indirect calorimetry analyses on Control and 
SynARKO mice using the CLAMS. Real-time monitoring showed VO2 consumption (Figure 
4.8 A and B) and VCO2 production (Figure 4.8 C and D) were both decreased in DHT treated 
SynARKO mice compared to Control mice treated with and without DHT. Data from Figure 
4.8 and Figure 4.9 are separated into dark and light cycles, due to known and well-studied 
behavioral difference of the mouse during the light and dark cycles.  In Figure 4.9 A and B, 
the respiratory exchange ratio (RER) was calculated and was significantly increased in Con-
DHT mice during light cycle. Although not significant, RER ratios of SynARKO-DHT mice 





Furthermore the increase in body heat after DHT treatment in Control mice is 
attenuated in SynARKO mice (Figure 4.9 C and D). This was most evident in the light cycle. 
During the light cycle of locomotor activity (Figure 4.9 E) and food accumulation (Figure 4.9 
G) a similar trend was observed in SynARKO-DHT mice. The trend being that SynARKO 
mice were protected from HA induced changes to energy expenditure. These data indicate a 
reduced metabolic rate and decreased energy expenditure after CNS AR deletion in female 
mice with DHT. To examine whether the difference observed in CLAMS were caused by 
change of body weight in SynARKO-DHT mice, we weighed the mice after CLAMS 
observation (Table 4.1 A). There was no significant difference in body weight between Con-
DHT and SynARKO-DHT mice (Table 4.1 A), suggesting that metabolic and behavioral 
changes observed in SynARKO mice are not due to changes in body weight. 
Discussion 
Hyperandrogenemia (HA) has been shown to cause impaired glucose tolerance and 
insulin resistance in women and in female rodent models (Manneras et al., 2007; van Houten 
et al., 2012). The mechanism of this HA-induced metabolic dysfunction is not fully understood. 
We developed a mouse model (Figure 4.1) that displayed pathophysiological serum androgen 
levels with normal body mass (Table 4.1) to ensure that the phenotypes were directly from 
androgens effects and not due to the onset of obesity. It has previously been demonstrated in 
our laboratory as well as by other researchers that DHT causes impaired glucose, insulin and 
pyruvate tolerance, and lowered hepatic insulin action (Andrisse et al., 2017; Brothers et al., 
2010; Yan et al., 2013; Wang et al., 2019) . The goal of this study was to determine the role of 





Infertility due to PCOS is a major problem affecting women of reproductive age all 
around the world. We hypothesized that CNS AR could mediate the HA induced infertility and 
acyclicity. We found no difference in age to puberty between Control and SynARKO female 
mice as indicated by vaginal opening (Figure 4.3 A). DHT is known to cause a reduction in 
numbers of estrous cycles as well as percent time spent in each stage. As shown in figure 4.3 
B and C control mice treated with DHT showed reduced number of cycles and increased 
percent time in met/diestrus stage. SynARKO mice treated with DHT did not display a rescue 
of the aforementioned reductions. A mating study (Figure 4.4) conducted revealed no 
significant difference in the reproductive viability between Control and SynARKO female 
mice. This is unsurprising as Wu et al have previously demonstrated that it is the pituitary AR 
and or theca ovarian AR during HA, that is most likely responsible for normal reproductive 
function (Ma et al., 2017; Wang et al., 2019).  
Findings from the Wu et al demonstrate that “androgens/AR signaling are important in 
the regulation of the preovulatory surge.” This conclusion is supported by our own findings of 
altered and reduced FSH secretion in SynARKO mice in estrous (Figure 4.6 B). LH levels 
remained relatively unchanged between control and SynARKO mice (Figure 4.6A). 
Interestingly we saw no differences in Gnrhr mRNA expression (Figure 4.10 B). However 
when looking further upstream of the HPG axis at the hypothalamic expression of Kiss1R, we 
show that Kiss1R expression is reduced in the hypothalamus as well as the AVPV and Arcuate 
nuclei (Figure 4.10 A). The altered levels Kiss1R in SynARKO female mice could certainly 
lead to altered FSH secretion levels (Pineda, Aguilar, Pinilla, & Tena-Sempere, 2010; 
Thompson et al., 2004). Although FSH levels differed, there was ultimately no significant 





These previous findings taken together led us to conclude that physiologically, 
SynARKO mice are similar to control mice in reproduction and metabolic function. However, 
their responses to DHT induced HA were not similar when considering metabolic function. In 
order to determine the effects of CNS AR on metabolic homeostasis, we performed a GTT and 
ITT at two different time points. The “early stage” time point was at 4 months of age and a 
total DHT insertion time of 2 months. The “later stage” time point was after 6 months of age 
and 4 months of total DHT exposure. As previously mentioned, HA or treatment with DHT 
causes hyperglycemia. The effects of DHT was apparent at the early stage in Figure 4.7A and 
B as Control and SynARKO blood glucose levels were significantly increased after treatment 
with DHT.  Remarkably, during the later stage of life, blood glucose levels of SynARKO-DHT 
female mice were significantly reduced in comparison to Con-DHT mice (Figure 4.7 E, F). 
SynARKO-DHT mice older than 6 months are seemingly protected from the increased blood 
glucose levels seen in Control-DHT mice after GTT (Figure 4.7 E, F).  
An ITT was performed to determine if insulin resistance cause by HA is rescued via a 
CNS AR knockout. Not to our surprise, in the early stage of Control mice, DHT caused 
increased insulin resistance as indicated by the overall higher blood glucose levels after a bolus 
injection of insulin (Figure 4.7 C, D). At the “late stage” SynARKO and Control mice treated 
with DHT showed a more comparable amounts of insulin insensitivity, as shown in their high 
blood glucose levels after being challenged with insulin in figure 4.7 G and H. To our surprise, 
the improvement in GTT was not coupled with an improvement in insulin sensitivity in 
SynARKO-DHT groups. Possible explanations include insulin resistance in other tissues such 





signaling molecules such as AKT, IR, GLUT, FOX-O1, and CREB between Control and 
SynARKO groups after DHT treatment could equally result in insulin resistance.  
Defects in energy homeostasis and expenditure is an important indicator of metabolic 
syndrome (Mauvais-Jarvis, 2011). While the role of AR and HA on energy expenditure in 
males has been well studied (Fernando et al., 2010; Khaw & Barrett-Connor, 1992; Yu et al., 
2008), the role of AR in female energy expenditure is not well known. We were able to analyze 
control and SynARKO female mice energy metabolism via a complete lab animal monitoring 
system (CLAMS). CLAMS revealed that after a 72 hour period of observation, DHT treated 
control mice consumed O2 and produced CO2 at the same levels (Figure 4.8 A and C). 
However, as quantified in Figure 4.8 B and D, SynARKO DHT treated mice showed 
significant decrease in O2 consumption and VO2 production versus DHT treated control mice.  
In order to take into account the light effects on rodent energy expenditure, energy 
expenditure data is displayed in both the light and dark cycle. Measures of RER, heat, motion, 
and feeding all followed a similar trend as follows; DHT increases the aforementioned 
categories in control female mice, while SynARKO-DHT treated mice brought those levels 
back down towards those of Con-no DHT female mice (Figure 4.9). The ability of SynARKO 
to be protected from the DHT induced changes in energy expenditure was only apparent in the 
light cycle and not in the dark cycle. In the dark cycle all parameters of energy expenditure 
such as movement, food consumption and heat production were equal.  This dramatic shift and 
reduction in energy expenditure in DHT treated SynARKO mice, leads us to believe that CNS 
AR plays a meditating role in HA induced metabolic and energy dysfunction. The ability of 
DHT treated SynARKO mice to behave as control untreated mice could also be reflected in 





cases of HA allows for the increased energy expenditure and imbalance noted in Con-DHT 
mice. However SynARKO-DHT female mice ameliorate these defects by protecting the mice 
from energy expenditure changes.  
 Our study reveals a crucial role for CNS AR on glucose and energy metabolism in 
middle- aged female mice with HA. Previous studies or AR deletion in the CNS such as that 
of Chang and colleagues was performed only in male mice and no GTT was conducted (Yu et 
al., 2013). To our knowledge, only one other group has attempted to delete brain expression of 
AR with HA in female mice. Caldwell et al, using a brain and hippocampus specific promoter 
(CamKII alpha cre) deleted AR in the aforementioned locations. After deletion of AR in the 
brains of female mice, Caldwell and colleagues then challenged 3 week old female mice named 
NeurARKO (Neuron Androgen Receptor Knock Out) with DHT pellets for 13 weeks. Mice 
were sacrificed at 16 weeks of age. NeurARKO mice treated with DHT did not develop 
anovulation, obesity, and dyslipidemia. Interestingly and similar to our findings, they were 
unable to rescue the acyclicity in these female mice caused by DHT treatment. As shown in 
Figure 4.3 B, Control-DHT and SynARKO DHT females had less than 1 total cycles. This lack 
of improvement in cyclicity after DHT treatment in both SynARKO and NeurARKO female 
mice leads us to believe that brain AR expression is not a target of HA induced acyclicity.  
Another similar finding between female NeurARKO and SynARKO mice are that both 
groups still exhibited a high blood glucose after exposure to DHT before 5 months old.  
NeurARKO female mice as mentioned earlier were treated for 13 weeks with DHT and 
sacrificed at 16 weeks of age, which is relatively similar to our “early stage” time GTT of 
SynARKO mice. We saw no improvement in the glucose intolerance caused by DHT treatment 





the NeurARKO group, in which the female mice were sacrificed at 16 weeks (~4months), we 
noted an improved GTT in middle-aged female mice (6-7 months old, 4-5 months DHT 
insertion) who had been exposed to DHT for a far longer period of time (Figure 4.7 B). This 
improvement in glucose tolerance in “late stage” SynARKO mice was unable to be ascertained 
by Caldwell and colleagues most likely due to experimental design differences. It is possible 
that if they had utilized adult female mice instead of postnatal mice, as well as extended the 
time of DHT exposure, they also might have seen improved glucose and energy metabolism.  
Further noted differences between our study and that of Caldwell et al, include the dose of 
DHT used to induce HA. Our group used a low dose of DHT (≤2mg, 4mm length of pellet), 
while Caldwell and colleagues used a relatively higher dose of 10mg of DHT (1cm length of 
pellet) of DHT.   
The brain as well as the CNS must now be recognized as sites of AR-mediated 
androgen action during HA. Here, using our low-dose DHT model of 4mm DHT pellets, we 
were able to induce HA in adult female mice and conclusively show that SynARKO female 
mice were protected from HA induced metabolic and energy dysfunction. Our results further 
demonstrate that CNS AR can be a target of treatment and future therapies to combat the 
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Table 4.1  
 




Whole body composition analysis was performed using EchoMRI. Mice from control and 
SynARKO (KO) groups were treated with DHT before measurements 21 days later. A.) Body 
weight B.)   Percent fat, lean and water were analyzed and quantified. Data were compared by 
One-Way ANOVA followed by Tukey’s posthoc test. (n=4 mice per group) 
 Weight(g) Fat (%) Lean (%) Water (%) 
     
Control 23.7 ± 0.7 11.95  ± 1.26 75.28  ± 1.01 60.95  ± 2.78 
Control-DHT 24.1 ± .42 12.2 ±1.69  74.25 ± .86  59.26 ± 0.68 
SynARKO  24.25 ±0.33  12.95 ± 1.09 73.96 ± 0.95 59.11 ± 0.45 
SynARKO-DHT 23.45 ± 0.85  11.69 ± 1.62 74.68 ± 1.27 58.70 ±  0.93 
 
 











Strategy for generation of SynARKO mouse 
Schematic overview of generation of Syapsin Cre- Androgen Receptor KO Mouse using cre-
lox recombinase technology. As shown, AR expression was specifically deleted in tissues of 










Confirmation of AR specific deletion in CNS 
A.) Qpcr confirmation of central nervous system specific disruption of Androgen Receptor. 
AR is significantly reduced in the hypothalamus of the SynARKO mice. The AR mRNA level 
was measured by quantitative RT-PCR in 4 different tissues- hypothalamus, ovary, pituitary, 
and liver. AR was significantly reduced (75%) in the hypothalamus of SynARKO (KO) mice 
compared with that in control (Con) littermates, but no difference in AR expression was 
observed in other tissues. Data are means ± SEM (n = 6–20).  B.) Protein confirmation of 
knockout. Actin protein was used as a loading control.  Western blotting was performed, and 
AR protein levels were quantified by densitometry in 3 independent experiments. The AR 
protein level was reduced significantly in hypothalamus of SynARKO mice (B1 and B2), 
whereas no change was observed in other tissues compared with those in controls. Data are 










SynARKO mice display same time of puberty and first estrus, and similar pattern of 
estrous cyclicity with HA 
Female puberty and cyclicity  A.) SynARKO females exhibited an age of puberty onset similar 
to that of control (Con) littermates (n = 10–16). B.) Percentage of time spent in each stage was 
not significantly different between control and SynARKO mice when treated with DHT (n 
=10–21). C.) The number of complete cycles was not significantly different between control 
and SynARKO mice when treated with DHT (n =10–21). P, proestrus; E, estrus; M, metestrus; 
D, diestrus. Values are means ± SEM. *=P<0.05 as determined by a two tailed Students T-test 








SynARKO female mice exhibited no difference in the numbers of litters compared to 
controls 
A.) Control and SynARKO female mice were introduced with a proven fertile male Control 
mouse, and the total numbers of litters per female were recorded during the 90 days (n =4).. 
B.) No difference in number of litters per female between control and SynARKO female.  NS, 
no significant difference.  C.) No difference in number of pups per female between control and 
SynARKO female. Values are means ± SEM relative to the control group as determined by a 













Hormone levels are not altered in SynARKO mice 
A.) and B.). Testosterone levels were measured at different stages of the estrous cycle (diestrus, 
proestrus and metestrus). There were no significant differences between control and 
SynARKO groups at each cyclic stage (A), and at combined stages (B)  (n= 6–20). C.) and D.) 
E2 levels were similar between control and SynARKO groups of diestrus, proestrus and 
metestrus (C) and at combined stages (D) (n =6–14). NS, no significant difference.  Values are 
means ± SEM relative to the control group as determined by a two tailed Students T-test. 


















LH/FSH levels are not altered in SynARKO mice  
A.) LH levels were measured during proestrus, estrus and metestrus. There was no change of 
LH levels in SynARKO mice compared with that in control mice at all three stages. B.) FSH 
levels were increased in SynARKO female mice during proestrus but significantly reduced 
during estrus when compared to control female. (n =8–15). Values are means ± SEM. 
















SynARKO mice with DHT have improved glucose tolerance compared to con-DHT 
A) Glucose tolerance test (GTT) and B) area under the curve of GTTof 4-5 month old mice, 
C) insulin tolerance test (ITT) and D) area under the curve of ITT of 4-5 month old mice. 
Control, Control-DHT, and SynARKO-DHT mice were subjected to (A) a 16-hour fasted, 2 
g/kg BW intraperitoneal GTT (n = 8 per group), (C) a 12-hour fasted, 0.3 U/kg BW ITT (n = 
7 per group); E-H were mice at 6-7 month old with the same test as the mice at 4-5 month old. 
Values are means ± SEM . *=P < 0.05, **=P < 0.01, ***=P < 0.001 relative to the control 
group as determined by a two tailed Students T-test or one way ANOVA followed by Tukey’s 













DHT treated SynARKO mice have similar energy expenditure to untreated control mice 
A.)  Real-time monitoring curve of oxygen consumption (VO2). B.) Quantification of O2 
consumption. C.) Real-time monitoring curve of carbon dioxide release (VCO2). D.) 
Quantification of carbon dioxide release. Values are means ± SD. *p < 0.05 relative to the 















DHT treated SynARKO mice have similar energy expenditure to untreated control mice 
A.) and B.)  Quantification of real-time monitoring curve of respiratory exchange ratio 
(RER = VCO2/VO2) during the light and dark cycle. C.) and D.) Quantification of calculated 
body heat during the light and dark cycle. E.) and F.) Quantification of locomotor activity 
during the light and dark cycle.  G.) and H.) Quantification of calculated accumulated food 
intake during the light and dark cycle. *P < 0.05,**P < 0.01, ***P < 0.001 relative to the 












A.) Kisspeptin Receptor mRNA levels were significantly reduced in the Arcuate and AVPV 
nuclei, as well as the hypothalamus of female SynARKO mice. B.) Important genes of pituitary 
function (KISSR, KISS1 and GnRHR) were measured by q-RT-PCR. Values are 
means ± SD. *p < 0.05 relative to the control group as determined by a two tailed Students T-
test. 
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